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ABSTRACT 
Several cellular processes such as cell cycle progression, apoptosis, cell adhesion and motility, cell growth, 
angiogenesis and differentiation are regulated by the MYC (here MYCN and c-MYC) proto-oncogenes. 
Elevated expression of MYC is present in a wide range of human tumors including Burkitt´s Lymphoma, 
neuroblastoma, medulloblastoma, colon cancer and glioblastoma.  In cancer, high MYC expression levels 
have been correlated with fast tumor growth and poor prognosis. Neuroblastoma, a heterogeneous childhood 
cancer has a broad clinical spectrum ranging from spontaneously regressing tumors to those with fast 
progression and an unfavorable outcome. One of the markers for poor survival is MYCN-amplification. 
Importantly, down-regulation of MYCN results in differentiation. While better treatment options has 
increased the overall survival for low-risk tumors, the survival of children with high-risk tumors has not 
improved and new therapeutic strategies such as targeting MYC are needed. Currently, there are no drugs 
directly targeting MYC available in the clinic. 
In paper I we demonstrated that several known c-MYC inhibitors also bind directly to MYCN and prevented 
MYCN/MAX interaction. We found that the affinities of the molecules correlated with growth inhibition of 
neuroblastoma cells. We further showed that the compounds lead to increased apoptosis in MYCN-amplified 
cells compared to non-amplified cells. In addition, treatment resulted in differentiation and lipid accumulation 
processes previously correlated to down-regulation of MYCN. These data show the proof-of-principle of 
directly targeting MYC. However, there is a great need for more potent and specific molecules targeting 
MYC. In paper II we have screened for new molecules targeting both MYCN and c-MYC. Using a cell-
based assay we identified six compounds that target both MYC proteins. The small molecule #2.7 was chosen 
for further characterization due to its ability to directly targeting MYC.  Treatment of MYCN-amplified and 
MYCN-non-amplified neuroblastoma cells with compound #2.7 lead to decreased proliferation in a MYCN-
dependent manner and to the inhibition of transformation by RAS and MYCN in vitro. Collectively, our 
results in paper I and II support the idea that direct targeting of MYC is a new strategy for cancer treatment.  
In paper III we demonstrated that MYCN upregulates the miR-17~92 cluster in neuroblastoma. Importantly, 
we showed that two members of the cluster miR-18a and miR-19a bind to and down-regulate the ESR1 gene 
encoding for the estrogen receptor-α (ER-α) thereby inhibiting differentiation of neuroblastoma cells. In 
contrast, ERoverexpression lead to neural differentiation. We further demonstrated ESR1 expression during 
normal development of the human sympathetic nervous system and showed a correlation between low ESR1 
levels and poor survival. Based on these results, we suggest that targeting MYCN regulated miRNAs could be 
another strategy to treat MYCN-amplified neuroblastoma.  
The transactivation domain (TAD) of c-MYC is a highly flexible region, which is necessary for all of MYC’s 
functions. In order to gain more information about the c-MYC-TAD we have performed structural studies in 
paper IV. Circular Dichroism  confirmed the presence of little secondary structure (about 9% α-helical and 
30% β-sheet) in the mainly disordered (61%) c-MYC-TAD. Small-angle light scattering analysis suggested 
that the overall structure is most probably that of an elliptical cylinder. Our results show that small-angle light 
scattering together with NMR and CD might be used in future studies to gain even more insight in the 
structure of the c-MYC-TAD. 
Taken together, two approaches to target MYCN-amplified neuroblastoma can be suggested based on the data 
presented in this thesis. The MYCN protein could either be targeted directly with small molecules or 
indirectly by using anti-miRNAs. We have identified several novel small molecules that target MYC that will 
be characterized and may have potential for further development. Importantly, we have also aimed to increase 
the knowledge concerning the structure of the c-MYC transactivation domain. This new information may 
contribute to the development of future tailored and selective targeting of MYC and its interaction partners 
and may also give further insight to MYC function. 
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1 
1. INTRODUCTION 
1.1 CANCER 
Cancer is a very complex and heterogeneous disease, in which cells divide uncontrollably 
leading to either benign or malignant tumors. Benign tumors do not metastasize, but the cell 
mass might cause local problems by damaging the surrounding tissue or by becoming malignant 
throughout progression of the disease 
1-3
. Malignant tumors can invade nearby or distant tissues 
through the blood or lymphatic system and they can form metastasis. Through the last decades 
it has been shown that tumorigenesis is a multistep progress  driven by genetic (mutations, 
chromosomal translocations, gene deletions, insertions or amplifications) and epigenetic 
alterations (chromosomal architecture, histone modifications or DNA methylations), which are 
either caused by environmental factors or are inherited (Figure 1) 
3
.  
In order for a genetically altered cell to develop into a cancer cell several control systems within 
the cell need to be overcome. The alteration could then lead to limitless proliferation, activation 
of invasion and metastasis, insensitivity to anti-growth signals, sustained angiogenesis, evasion 
of apoptosis and self-sufficiency in growth signals 
4, 5
. These mechanisms are hallmarks for 
developing tumors. Genomic instability and tumor promoting inflammation are supporting 
factors for developing cancer cells. In addition two more hallmarks for cancer have been 
emerging over the last years including deregulation of cellular metabolism as well as avoiding 
the destruction of the cancer cell by the immune system 
4, 5
. 
 
Figure 1. Possible model for the development of cancer. After the inactivation of a tumor 
suppressor in a cell leading to increased proliferation, genes involved in DNA repair are mutated. 
This is followed by mutations in oncogenes and further mutations in oncogenes or tumor 
suppressors leading to the development of cancer. Each new alteration can result in an advantage 
in e.g cell growth or proliferation for the cell. However, there are also disadvantages alterations 
for the cell leading to growth arrest and apoptosis. 
2 
Each cancer is a very unique and elaborated system, consisting of individual mutations and 
genetic or epigenetic alterations as mentioned above 
1
. In addition, the tumor does not only 
consist of cancer cells but also contains normal cells such as fibroblasts, blood vessels, immune 
and/or stromal cells, which are part of the microenvironment of the tumor and involved in 
tumorigenic process 
6, 7
. Cellular functions are tightly regulated by oncogenes and tumor 
suppressors which are deregulated in cancers 
8
.The function of oncogenes and tumor 
suppressors is explained in the next two chapters below. As mentioned above several mutations 
in both oncogenes and tumor suppressors are necessary in order to transform a normal cell into 
a cancer cell. Since these mutations do not all occur at the same time it explains the increasing 
incident of cancer with increasing age. However, cancer can also arise in children where they 
have less genetic alterations. The tumors in children originate from progenitor cells that are part 
of the developmental programs. In order for the pre- and postnatal development cellular 
processes like proliferation and apoptosis regulate and form tissues within the child. The highly 
proliferative cells in developing tissue together with genetic alterations in these processes can 
lead to cancer 
9
. 
1.1.1. Oncogenes 
In normal cells the so called proto-oncogenes are involved in normal physiological processes 
including proliferation, cell growth, differentiation and/or apoptosis. The products of these 
genes are often transcription factors, chromatin remodelers, growth factor receptors, growth 
factors, signal transducers and/or regulators of cell death (Figure 2) 
10
.  
 
Figure 2. Examples of known oncogenes (*) in the signaling cascade. Growth factors e.g. ErbB are 
binding to their tyronsine kinase receptor, e.g. ErbB receptor, which then gets activated through 
phosphorylation. The phosphotyrosine residues are then bound by Growth factor receptor-bound protein 
2 (GRB), which in turn activates guanine nucleotide exchange factor (SOS), which in turn then activates 
RAS. Afterwards RAF is activated by RAS through phosphorylation, which in turn phosphorylates MEK 
leading to phosphorylated ERK. ERK then phosphorylates transcription factors e.g. MYC leading to 
their activation.  
  
 
3 
Due to their involvement in these cellular processes proto-oncogenes can be turned into 
oncogenes. Alterations of the oncogene can occur through chromosomal translocation resulting 
in overexpression of the gene, mutations or gene amplification leading to an increased or 
deregulated expression of the gene. Furthermore, mutations in the oncogene can lead to a 
structural change of the oncoprotein, leading e.g. to decreased degradation. These alterations 
lead to cells with advantages to normal cells promoting cell growth and proliferation and/or pro-
survival signaling in these cells 
10, 11
. The proteins encoded by these genes often have multiple 
functions within a complex network. In their deregulated form oncogenes might be more 
important for the cancer cell compared to a normal cell. This might be due to fact that the gene 
expression and the signal transduction of the cancer cell has been shown to be different 
compared to a normal cell.  
The first oncogenes identified in human cancer cells were the RAS genes, coding for small 
GTPases, which are involved in cellular signal transduction through e.g. the mitogen-activated 
protein kinases. The RAS genes often carry point mutations or they are amplified in wide range 
of human cancers such as pancreatic cancer, lung cancer and melanoma 
12, 13
. Another family of 
oncogenes, called MYC, is deregulated in a large number of human tumors. This family of 
oncogenes encodes for the transcription factors c-MYC, MYCN and MYCL, which will be 
described in more detail below. In Burkitt’s Lymphoma (BL) c-MYC is translocated to one of 
the Ig loci, while c-MYC is amplified in e.g. breast cancer, colon cancer and gastric cancer, 
MYCN is amplified in neuroblastoma. All these alterations lead to the overexpression of MYC 
promoting cell growth and proliferation 
14
. The ALL1 protein is part of a multiprotein complex 
that remodels, acetylates, deacetylates or methylates nucleosomes and free histones. In acute 
lymphopatic leukemia (ALL) the gene encoding for ALL1 can fuse with over 50 different genes 
leading to chimeric proteins, which in turn deregulate homeobox and microRNA genes
15
. The 
genes of growth factors like fibroblast growth factors (FGF) or insulin growth factors (IGF) 
have been found overexpressed in several types of cancer leading to increased signaling. 
Additionally, receptors of growth factors including epidermal growth factor receptor (EGFR) 
have been found to be altered by e.g. deletion of their ligand binding domain leading to 
constitutive activation (13). BCL-2, which exerts pro-survival functions in the cell, is found to 
be translocated in e.g. follicular B-cell lymphoma. BCL-2 is inhibiting the pro-apoptotic BCL-
2-associated protein (BAX) preventing the cell from undergoing apoptosis 
16, 17
. BAX, a pro-
apoptotic protein of the BCL-2 family, would in turn trigger Cytochrome c release thereby also 
activating caspases, which would lead to apoptosis. 
 
1.1.2. Tumor suppressor genes 
With the discovery of “proto”-oncogenes it was hypothesized that genes exist, which oppose or 
control functions of oncogenes and could suppress tumorigenesis. These genes are called tumor 
suppressor genes. In order to deactivate the recessive tumor suppressor genes both alleles 
4 
normally have to be inactivated 
18, 19
. Three properties of classical tumor suppressor genes have 
been defined. The formation of tumors is accelerated if a germline mutation exists since then 
only one additional mutation in the second allele is necessary. At last, the frequent inactivation 
of the same gene should be evident 
19
. 
One very well-known tumor suppressor is p53, which is deregulated in over 50% of human 
cancers 
20, 21
. p53 is also known as the guardian of the genome since it is involved in keeping 
the stability of the genome e.g. activation upon DNA-damage. It is a transcription factor, which 
regulates downstream targets involved in cell cycle control through e.g. p21, apoptosis e.g. 
BAX and senescence e.g. p21 and is activated from different forms of stress including DNA 
damage, oncogene activation, hypoxia and irradiation 
19
. The p21 protein is cycline-dependent 
kinase inhibitor and is therefore involved in regulation of the cell cycle. The retinoblastoma 
protein (RB) was the first tumor suppressor discovered, it is as p53 also involved in regulating 
cell cycle check points 
22
. RB represses gene expression by recruiting histone deacetylases and 
chromatin remodeling factors. Furthermore it binds to the E2F family of transcription factors. 
The E2F family members are involved in the positive regulation of proliferation 
23
. Another 
group of tumor suppressor proteins are those regulating ligand-mediated signaling pathways 
such as Activated protein C (APC), which interacts with β-catenin in the absence of Wnt 
signaling leading to the phosphorylation and degradation of β-catenin and inhibiting activation 
of c-MYC and cyclin-D1
24, 25
. The two breast cancer suceptibility genes (BRCA) are examples 
of tumor suppressors that are involved in the DNA damage response. Both play key functions in 
homologous recombination and non-homologous end joining 
19
. Another group of tumor 
suppressors is involved in protein ubiquitination and turnover. The von Hippel-Lindau protein 
ubiquitinates HIF-α leading to its degradation by the proteasome thereby indirectly inhibiting 
angiogenesis and glycolysis induced by hypoxia-inducible factor 1 (HIF-1α) 26. 
Even though most tumor suppressors need two alleles to be mutated in order to be inactivated, 
there are some exceptions like the gene encoding the CDK inhibitor p27
Kip1
. In these cases one 
of the alleles is either haploinsufficient for tumor suppression or epigenetic silencing leads to 
the inactivation of one of the alleles 
19
. In mice, older animals that lost one copy of the kip1 
gene develop spontaneous tumors. In addition, they have been shown to be sensitive to 
chemical induced carcinogenesis. Furthermore there is evidence that altering one allele of 
p21
Cip1
, p57
Kip2
 and p18
Ink4c 
might be enough to inactivate the tumor suppressive function of 
these genes 
19, 27
. 
 
1.1.3. MicroRNAs in cancer 
MicroRNAs (miRNAs) were first discovered as a large group of noncoding RNAs, which in 
most cases inhibit the translation and stability of messenger RNAs (mRNAs). Their target genes 
  
 
5 
are involved in wide range of cellular processes including cell cycle regulation, differentiation, 
apoptosis, metabolism, migration and stress responses 
28-30
.  
Over 50% of all miRNA genes are clustered and transcribed as multicistronic RNA transcripts. 
After processing of the multicistronic RNA transcript, a single miRNA consists of a single-
stranded 19-25 nucleotide (nt) long ncRNA sequence, which is now able to bind to the 3’ UTR 
region of the targeted mRNAs resulting in the degradation and reduction of translation of these 
mRNAs. Each miRNA is predicted to target over 100 mRNAs and to contribute to the 
complexity each mRNA can be targeted by several different miRNAs 
28-31
. 
MiRNA expression is often deregulated in cancer as a result of chromosomal rearrangements, 
amplification, mutations or deletions, which mostly leads to their repression compared to the 
levels in normal tissue. The expression of miRNAs is very tissue specific and therefore they can 
act as oncogene in one tissue and as tumor suppressors in other tissues 
30
. One example is 
themiR-17-92 cluster, which is oncogenic in several tumor types including neuroblastoma  
32
 
but functions as a tumor suppressor in prostate cancer 
30, 33
. Another example is miR-222, which 
targets the KIT oncogene in erythroblastic leukemia and the PTEN tumor suppressor in lung and 
liver cancer 
30, 33
. 
 
1.2. PROTEIN STRUCTURE 
In cells a great variety of proteins exists, which all differ in their amino acid (aa) sequences 
(primary structure). Understanding the folding of this linear sequence into first secondary 
structure elements followed by tertiary or even quaternary structure is not completely 
understood and has been the focus of many groups during the recent decades 
34
. 
The α-helix and the β-sheet are the most common secondary structure elements, which are often 
connected by turns or loose flexible loops. AAs can be divided in different groups according to 
the properties of their side chains, which are: nonpolar, polar, aromatic positively or negatively 
charged. These properties combined with their size have been correlated with a preference for a 
certain type of secondary structure. While amino acids containing an aromatic ring 
(phenylalanine, thryptophan, tyrosine) or a bulky side chain (isoleucine, threonine, valine) are 
more common in β-sheets 35, short polar side chains (aspartic acid, asparagine, serine) , with no 
side chain (glycine) or with a cyclized side chain (proline) are preferably found in reverse turns. 
Except of arginine, which seems to have no preference, all other amino acids (alanine, cystein, 
glutamine acid, histidine, lysine, leucine, methionine, glutamine) favor α- helices 36, 37. 
However, the protein fold is not only dependent on the amino acids but also on inter-residue 
interactions including hydrophobic, aromatic or polar contacts
38
. Furthermore, rules can be 
found for the distribution of residues within a certain secondary structure 
38
. The properties of 
the solution like pH, salt concentration or the temperature play a role for secondary structure 
39
. 
6 
1.2.1. Globular proteins 
The tertiary structure of a globular protein has hydrophobic amino acids in its core and 
hydrophilic, charged amino acids at the surface of the protein. Small globular proteins can fold 
by self-assembly 
40
. Large globular proteins normally consist of several domains 
41
. However it 
is still not clear how only the amino acid sequence can result in a three-dimensional structure 
42, 
43
. For a long time it was thought that proteins adapt their tertiary structure through a number of 
partially structured intermediates, but the chymotrypsin inhibitor 2 protein was shown to fold in 
a two-state transition without intermediates
44
. For the intermediates of some proteins 
stabilizations by chaperones is necessary during the folding process 
41
. The folded, native 
conformation of the protein is normally the lowest free energy state. 
 
1.2.2. Intrinsically disordered proteins 
Besides completely folded proteins and multidomain proteins that are separated by flexible 
linkers completely intrinsically disordered proteins (IDPs) exist. During the last years it has 
become clear that IDPs are a very broad class of proteins with different types of functions 
including transcription factors and proteins involved in cellular signal transduction, protein 
phosphorylation, regulation of self-assembly of large multiprotein complexes and the storage of 
small molecules 
45-48
. IDPs normally have a small content of hydrophobic amino acids, which in 
folded globular proteins built the inner core of the protein. Instead the proportion of charged and 
polar amino acids is high 
45, 47
. Structural characteristics of IDPs can further be divided in 
extended or compact disordered state with molten globule like properties. Furthermore, IDPs 
involved in transcriptional activation could be divided in classes according to their aa 
composition. These proteins contain often acidic, proline-rich or glutamine- rich activation 
domains 
49, 50
.  
Proteins with molten globule properties have been described as part of the folding of a protein 
gaining an ordered structure and it has not been seen as a normal state of a protein within the 
cell. Molten globule proteins contain native like secondary structure with little structured 
segments and little to no tertiary structure. Since IDPs often have several binding partners their 
flexibility allows for adaptation to the size and structure of their interaction partners, leading to 
different conformations of the IDP itself 
51, 52
. Another advantage of the disordered state is the 
larger radius, in which it can capture its binding partners. During the binding process many 
IDPs gain secondary and/or tertiary structure and undergo a folding-upon binding process. The 
flexibility of an IDP also allows wrapping around the binding partner. The transition from 
disordered to an ordered associated with entropic costs that have to be balanced through a 
favorable enthalpy. Folding-upon-binding results in complexes that normally have a low 
affinity but a very high specificity leading to two different advantages 
49, 50, 52
. Transcription 
factors can easily undergo post-translational modifications, which can modulate the protein for 
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its conformational requirements to bind their target protein. Such modifications are performed 
by phosphatases, acetylases, deacetylases, kinases, methylases as well as ubiquitin ligases. 
Increased numbers of phosphorylation sites have been reported for IDPs. For IDPs involved in a 
signaling pathway, the complex will easily dissociate after the signaling is complete. However, 
some IDPs remain in their disordered state after binding to their binding partner 
49, 50, 52
.  
In order to study IDPs biophysical methods such as circular dichroism (CD), fluorescence 
spectroscopy, NMR spectroscopy, Raman spectroscopy and small angle X- ray scattering 
(SAXS) can be used. X-ray crystallography is mostly used for IDPs bound to one of their 
ligands. These methods are described below in the experimental methods section. 
 
1.2.3. Transcription and transcription activation domains 
Transcription is achieved by three different RNA polymerases in eukaryotes. While RNA 
polymerase I (Pol I) transcribes genes for ribosomal RNA (rRNA), messenger RNA (mRNA) 
coding for proteins and/or miRNAs and small nuclear RNA (snRNA) are transcribed by RNA 
polymerase II (Pol II). The third RNA polymerase (Pol III) transcribes 5S rRNA and transfer 
RNA (tRNA) 
53
. For RNA Pol II to transcribe genes several transcription factors are needed in 
order to form the transcription initiation complex such as the Transcription factor II D (TFIID) 
complex consisting of the TATA-box binding protein (TBP) and TBP- associated factors 
(TAFs) 
53
. The TATA-box sequence that is located some base pairs upstream the initiation site, 
is recognized by TBP followed by recruitment and association of additional transcription factors 
(TFIIA, TFIIB, TFIIE, TFIIF and TFIIH) 
54
. After the DNA double strand is separated and Pol 
II has bound to the initiation complex, RNA is synthesized 
53
.  
In order to regulate gene expression by Pol II complex, DNA regulatory sequences are bound 
by transcriptional activators and repressors. This mechanism allows genes to be turned on or 
off. Proteins involved in activation or repression often have several domains that are connected 
by flexible linkers. The most important domains for these proteins are a DNA binding domain 
and the transcriptional activation domain (TAD), which is often bound by a variety of cofactors, 
repressors and proteins of the transcriptional complex. Even though the biological functions of 
TADs have been studied, much remains unclear regarding their structure and the molecular 
mechanism of interaction. There is no real sequence homology between different TADs and due 
to their disordered state and multiple binding partners their structures are not easy to assess. 
TADs have been proposed to interact with their binding partners through short hydrophobic 
stretches 
55, 56
. 
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1.3. THE MYC FAMILY 
After the identification of the human homologue of the v-gag-myc gene in Burkitt’s Lymphoma 
(BL) in the early 1980s [cellular MYC (c-MYC)], two more genes called MYCN and MYCL 
were discovered. The name MYC is derived from myelocytomatosis. While MYCN was found 
to be amplified in neuroblastoma MYCL was identified in small lung carcinoma
57, 58
. MYC is 
involved in a number of cellular processes such as apoptosis, proliferation, cell growth, 
inhibition of differentiation, metabolism, telomerase activity, cell adhesion and motility as well 
as angiogenesis. Deregulation of MYC can lead to uncontrolled cell proliferation, 
immortalization, independence of growth factors, escape from immune surveillance and 
genomic instability. Both normal functions as well as results of deregulated MYC will be 
described below 
14, 58, 59
. 
 
1.3.1 MYC expression and regulation 
In general c-MYC mRNA is expressed at low levels and also present in normal proliferating 
cells 
60
. A tight regulation on multiple levels such as transcription initiation, transcriptional 
elongation, translation, stability of mRNA has been shown. For example it has been shown that 
the H3-histones surrounding the c-MYC gene are significantly more hyperacetylated, while no 
change in the levels of H3-H9-methylation could be found 
60
. In 1986, c-MYC was the first gene 
identified to be regulated by transcriptional elongation control 
61
. 
There are actually four c-MYC promoters, but the level of initiation is very low for the P0 and 
P3 promoters, since they lack the TATA-box binding motif. The TATA-box binding motif of 
the P1 Promoter is less optimal and transcription is started with up to 25% at this starting site. 
The P2 promoter contains an optimal TATA-box with two additional initiator (INR) elements, 
which explains why this promoter is used for transcriptional initiation in up to 90 %. There are 
two different proteins produced, the larger one with a size of 67 kDa from a start codon in the 
end of the first exon and a smaller one with 64 kDa, which is the main protein product from an 
ATG start codon in the second exon 
60, 62
. 
During gastrulation c-MYC and MYCN are expressed in contrasting patterns 
63
. Both genes are 
differentially expressed in all types of tissues during embryonic development. While MYCN 
expression is restricted to the developing kidney, intestine, brain, lung and heart and high 
expression has also been found in the neuroepithelium, c-MYC is expressed in most tissues 
64-66
. 
MYCL expression is restricted to certain tissues e.g. fetal skin and specific stages of 
development. Knockout mice of the c-myc gene die at embryonic day 10.5, in contrast mycn 
knockout mice die at embryonic day 11.5 
67, 68
. In c-myc null mice an introduction of the mycn 
gene in the c-myc locus resulted in viable mice with only few developmental defects in the 
exception of skeletal muscles
69
. In the adult c-myc is expressed in nearly all tissues, while mycn 
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is very low or absent 
70
. MYCL is expressed in the lung in the adult. The levels of the MYC 
genes are low in non-dividing cells, but the response to growth stimuli is fast and the expression 
of the gene is rapidly elevated. The expression of c-MYC correlates strongly with cell 
proliferation and levels of c-MYC in the nucleus are constant throughout the whole cell cycle 
71, 
72
. MYC genes underlie high levels of control and in response to anti-proliferative signals the 
MYC gene is immediately down-regulated if the cell is not proliferating. In case the gene would 
not be down-regulated after anti-growth stimuli, the cell would undergo apoptosis due to 
regulatory mechanisms in the cell measuring MYC-levels 
73, 74
.  
 
1.3.2. MYC protein 
MYC consists of the N-terminal transactivation domain (TAD), the central domain and the C-
terminal basic helix loop helix leucine Zipper domain (bHLHZip) that is able to bind to DNA. 
The C-terminal bHLHZip domain as well as MYC box I and II (MB) in the TAD are very 
conserved regions (Figure 3). In addition there are two more MYC boxes (MB III and MB IV), 
which are conserved in c-MYC and MYCN and c-MYC, MYCN and LMYC respectively 
58, 75, 
76
.  
 
Figure 3. Schematic overview of the MYC and MAX proteins. The MYC protein contains 
several conserved domains. The N-terminal transactivation domain harbors two conserved 
regions MYC-box (MB) I and II. MB III and IV are located within the central domain, while the 
C-terminal region consists of a basic helix-loop-helix Zipper domain (bHLHZip). The MAX 
protein also contains a bHLHZip domain. 
 
The c-MYC TAD consists of the residues 1-143 and contains MB I (44-63) and MB II (128-
143). MB I is involved in gene activation as well as the degradation of MYC by 
phosphorylation of T58 and S62. The deletion of MB I does not have major effects on MYC 
function. Hot spots for mutations have been found in MB I at residues T58 and S62 as well as 
the surrounding sequence in BL 
58, 77
. In contrast to MB I, MB II is crucial for most of MYCs 
functions and the deletion of MB II leads to a strong reduction of its transcriptional activation 
and transformation capacity. In MB II E138 has been identified as a hot spot for mutations in 
BL 
58
. Two domains with transactivating activity have been localized. The first domain is 
situated next to MB I comprising residues 1-41. The second domain is overlapping MB II 
involving residues 66-127. Also two domains for transcriptional repression have been localized. 
10 
While one domain is overlapping MB II the second domain is localized between MB I and MB 
II (residues 92-106) 
78
. Recently it has been shown that MB III, which is located in the central 
domain, is involved in transcriptional repression and is able to negatively regulate 
transformation by increasing MYC’s potential to induce apoptosis. Deletion of MB IV resulted 
in the impairment of MYC’s ability to bind to DNA as well as in hyperactive G2 arrest. 
Furthermore, MB IV was shown to be important for induction of apoptosis and might play some 
role in transformation 
79
. The bHLHZip domain of MYC is heterodimerizing with Max leading 
to DNA binding. This domain has also been implicated in the oligomerization of MYC 
produced in bacteria. However, this did not seem to be a physiological mechanism. In addition, 
this domain is necessary for MYC’s ability to cellular transformation 78. 
1.3.2.1. Structure of the MYC protein 
In the unbound form MYC is an IDP (see section about intrinsically disordered proteins) 
meaning that upon binding MYC will form secondary and eventually tertiary structure. The 
structure of the C-terminal bHLHZip domain of c-MYC has been determined in a heterodimer 
with MAX bound to DNA
80
. Upon interacting with MAX c-MYC forms two α-helices that are 
connected by a loop enabling the complex to bind to DNA. However, little is known about the 
structure of the N-terminal TAD. This domain has been shown to interact with a large number 
of different binding proteins, thereby probably obtaining different confirmations. Recent efforts 
have revealed some structural insights in parts of the c-MYC-TAD. The domain without 
interaction partner has been predicted to have about 20% α-helices and some β-sheet strands 81. 
Indeed, the presence of short α-helical segments has been reported. Two short α-helices have 
been reported for the residues 26-34 and 47-52. In addition a short β-sheet strand stretching 
from residues 22-33 has been found 
81, 82. Predictions have further indicated a partly α-helical 
fold for the region comprising residues 92-167. Within this region lies the most hydropobic part, 
which is located in MB II 
78
. Our study (paper IV) also indicates some α-helical structure as 
well as some β-sheet strands. Furthermore the SAXS analysis we performed, implicated 
structured domains that are connected by flexible linkers within the c-MYC-TAD. The c-MYC-
TAD alone was also found to oligomerize (paper IV). 
 
1.3.2.2. Post-translational modifications of MYC 
Nuclear proteins involved in regulation of gene transcription are often targets of several 
different signal transduction pathways. Therefore these proteins are regulated at several 
different steps by post-translational modifications. MYC has been reported to be 
phosphorylated, ubiquitinated, acetylated, glycosylated and sumoylated 
83
. 
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1.3.2.2.1. Phosporylation of MYC 
Several phosphorylation sites have been identified for MYC including T58, S62, S71, S82, 
S162 and S164 in the N-terminal TAD. Furthermore two additional clusters have been 
identified including residues T247, T248, S249, S250, S252 as well as T343, S344, S347 and 
S348. The two phosphorylation sites T58 and S62 have been well described due to their 
involvement in MYC degradation. Both amino acid residues are targeted by the kinase glycogen 
synthase kinase 3 (GSK3) for T58 as well as proline-directed kinases such as mitogen-activated 
protein kinase (MAPK), c-Jun N-terminal kinase (JNK) and cyclin-dependent kinase 1 (CDK1) 
for S62 phosphorylation. The different kinases phosphorylating S62 are involved in several 
different signaling pathways. In order to modify T58, S62 has to be phosphorylated by one of 
the kinases. The phosphate is then able to bind specifically in the substrate recognition domain 
of GSK3, enabling for phosphorylation of T58. Other phosphorylation sites such as S71, S82, 
S293 and S344 are also close to prolines next to them, which makes them potential substrates 
for proline-directed kinases. To date no kinases have been identified that might be involved in 
the modification of these serines.
84-86
.  
 
1.3.2.2.2. Ubiquitination and degradation of MYC 
Through poly-ubiquitination of lysine residues, proteins can be targeted for degradation through 
the 26S proteasome. The activity of the MYC protein is tightly regulated and the protein has a 
short half-life of 20-30 minutes. After phosphorylation of both T58 and S62, S62 is 
dephosphorylated by the protein phosphatase 2A. The F-box protein FBW7 is now able to bind 
MYC, which is only phosphorylated at T58. FBW7 is a subunit of the SKP1-CUL1-F-box 
protein (SCF) ubiquitin-protein isopeptide ligase complex, which is able to poly-ubiquitinate 
MYC leading to its degradation. In addition, MYC can also be ubiquinated through the SCF-
SKP2 complex. It has been suggested that this interaction leads to the ubiquitinylation of MYC 
leading first to the activation of the transcriptional activity of MYC followed by its 
degradation
87-91
.  
 
1.3.2.2.3. Acetylation of MYC 
Several proteins binding to the c-MYC-TAD are additionally also interacting with histone 
acetyltransferases, which are not only able to acetylate histones but also MYC itself. Two 
proteins, p300 and mGCN5 are able to modify lysines (K298, K323, K326, K341 and K355) 
which is located within the nuclear location sequence (NLS). Other lysines within MYC such as 
K417 in the Zip can also be acetylated 
92
. Recently, these six lysines within c-MYC were 
mutated to arginines leading to increased cell proliferation as well as the ability to transform 
cells and to enhance tumor growth in a NB and a breast cancer model 
93
. The lysines in and 
12 
close to the c-MYC-TAD  (K143, K148 and K157) have also been reported to be acetylated 
94
. 
Acetylation can also interfere with ubiquitinylation since both target lysines. Through 
acetylation of MYC it has been show that ubiquitinylation of MYC is decreased suggesting that 
the MYC protein can be stabilized
95, 96
.  
 
1.3.2.2.4. Glycosylation of MYC 
Serine and threonine are amino acids that can be modified by O-linked N-acetylglucosamine 
(O-GlcNAc), which can be linked to the hydroxyl side chain of the two amino acids. O-
GlcNAcylation has been shown to play an important role during cell proliferation as well as 
chromatin modulation. Manipulations of O-GlcNAc levels affect the migration and or 
invasiveness of e.g. breast and lung cells 
97
. Furthermore increased O-GlcNAcylation has been 
reported for several types of cancer 
97
. MYC is also glycosylated close to the or within the c-
MYC-TAD. T58 has been shown to be O-GlcNAcetylated and thereby MYC protein stability is 
increased. However, the status of MYC glycosylation still needs to be further examined 
98, 99
. 
 
1.3.2.2.5. Sumoylation of MYC 
During sumoylation one or several small ubiquitin-like modifier (SUMO) proteins are coupled 
to lysines. Higher eukaryotes have three SUMO paralogs. There are three effects of sumoylation 
on their target proteins, namely competition with acetylation and ubiquitinylation, creation of 
new interactions or inhibition of protein-protein interactions. Therefore SUMOylation plays a 
role in different cellular processes like transcription, DNA repair and the structure of 
chromosomes. It has been reported that MYC can be SUMOylated on a lysine between MB IV 
and the bHLHZip domain of both c-MYC and MYCN. The effects of SUMOylation are not 
entirely clear, however it has been suggested that it might play a role in controlling misfolded 
MYC proteins 
100
. 
 
1.3.2.3. MYC interaction partners 
During the last decades several binding partners to both the C-terminal bHLHZip domain as 
well as the N-terminal TAD have been identified (Figure 4). One of the best characterized 
interactions is the heterodimerization of c-MYC and MAX, which will be described below. For 
some binding partners only little is known and much remains to be investigated. Especially the 
molecular basis underlying binding of the MYC-TAD and its binding partners still needs to be 
examined. A selection of binding partners to both domains will be described below in more 
detail 
75, 78
. 
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1.3.2.3.1. Binding partners to the N-terminal domain of MYC 
1.3.2.3.1.1. TRansformation/tRanscription domain-Associated Protein       
(TRRAP) 
The TRRAP protein is conserved throughout many species and with 3828 amino acids it has a 
very large size. It is a member of the phosphatidylinositol 3-kinase-related kinase (PIKK) 
family, which is related to PI3-kinase (PIK) family 
101
. The proteins of this family play a major 
role in DNA damage detection and signaling. In mammalians this family includes proteins such 
as mammalian TOR (mTOR), Ataxia-telangiectasia mutated (ATM) or the suppressor of 
morphogenesis in genitalia-1 (SMG-1). These proteins share several motifs, like the FATC 
(FRAP, ATM and C-terminus) domain, the FAT (FRAP, ATM and TRRAP) domain as well as 
the PIK-like domain. However TRRAP lacks the conserved aa’s necessary for the catalytic 
activity of these proteins and therefore lacks kinase activity. Instead TRRAP might have 
evolved as an adaptor or scaffold for protein-protein interaction as well as for multiprotein 
assembly 
101
. TRRAP serves as a platform for regulatory factors and protein complexes 
involved in the coordination of processes modulating chromatin as well as in transactivation and 
repression of genes. It is a very common subunit of different histone acetyltransferases (HAT) 
complexes like the general control nonrepressible-related (GCN5) acetyltransferases (GNAT) 
HAT family and the MOZ, Ybf2/Sas2, Tip60-related (MYST) HAT family 
102
. 
TRRAP has been found to be involved in embryonic development as well as cell cycle 
progression 
103
. The recruitment of TRRAP by c-MYC to promoters transcribed by Pol I has 
previously been shown
101
. Two regions in c-MYC have been reported to be bound by TRRAP. 
One region in c-MYC is at MB II and another region closer to the N-terminal end of the protein. 
The main region of TRRAP involved in this interaction has been located to a stretch spanning 
aa 1899-2026. Furthermore the region comprising aa residues 1261-1579 as well as residues 
3402-3828 has been shown to be involved in inhibition of c-MYC-dependent transformation 
either through direct binding to c-MYC or by sequestration of a downstream target of the c-
MYC/TRRAP pathway 
103-105
. In a glioblastoma cells TRRAP knockdown has led to an increase 
in apoptosis and induction of differentiation in brain tumor initiating cells (BITC). Furthermore, 
a decrease in tumor burden and an increase in overall survival in a glioblastoma xenograft 
model. These results suggest a close involvement of TRRAP in transformation of cells and as a 
result tumor formation 
106
. 
14 
 
 
Figure 4. MYC and its binding partners. The most important domains in MYC like the 
transactivation domain (TAD), the MYC-boxes (MB) I-IV as well as the basic helix-loop-helix 
domain (bHLHZip) are marked. Regions for interaction by MYC and their binding partners are 
indicated. Adapted by Tu et al. (2014), with the permission from the publisher. 
 
  
 
15 
1.3.2.3.1.2. TATABinding Protein (TBP) 
TBP plays a central role in gene expression, interacting with all three RNA polymerases 
through the formation of complexes such as selectivity factor (SL) 1, TFIID or TFIIIB. TBP is 
an important subunit of the TFIID and SPT-ADA-GCN5 acetyl-transferase (SAGA) complexes, 
which bend and unwind DNA. TBP has been shown to bind to an extended sequence of the c-
MYC-TAD. Upon binding an induction of protein conformation within the c-MYC-TAD has 
been reported. Furthermore TBP has been suggested as an important target for the c-MYC-TAD 
during transcriptional initiation 
107, 108
.  
 
1.3.2.3.1.3. Bridging INtegrator 1 (also Box-dependent myc-INteracting 
protein 1; Bin-1) 
The tumor suppressor BIN-1 contains a N-terminal Bin-Amphysin-Rvs (BAR) domain and a C-
terminal sarcoma (SRC) homology domain as well as a neuron-specific endocytic function 
domain (NTS). Furthermore interaction of BIN-1 with c-MYC through the MYC-binding 
domain (MBD) has been reported and selectively inhibiting MYC’s oncogenic and 
transactivation properties. Several tissue specific splicing variants have been identified, some of 
which have been implicated to play a special role in tumorigenesis. This may be a result of 
some isoforms, which abolish the ability of BIN-1 to interact with c-MYC 
109
. 
In a structural binding study of the aa 1-88 of c-MYC to the SH3 domain of BIN-1 no folding 
upon binding could be detected 
81
. Deletion of the MBD resulted in loss of the ability of BIN-1 
to interact with c-MYC and therefore lead to uninhibited c-MYC mediated tumorigenesis 
110
. 
The tumor suppressing function of BIN-1 has also been shown to be exerted through a MYC-
dependent and a MYC-independent mechanism like the inhibition of RAS co-transformation 
110
.  
 
1.3.2.3.1.4. F-Box and WD repeat domain-containing 7 (FBW7; FBXW7) 
Three classes can be found for F-box proteins depending on the presence of WD40 repeats 
(FBXW), leucine repeats (FBXL) or the absence of both domains. The F-box proteins are 
adaptor proteins for SCF ubiquitin ligase complexes and substrate variation is depending on the 
F-box protein bound by the complex and their target proteins. FBW7 has been shown to 
regulate processes such as cell growth, proliferation, differentiation and survival through 
degradation of its target proteins such as c-MYC, cyclin E, NOTCH and c-JUN. These proteins 
are targeted by ubiquitinylation through FBW7 at specific residues and down-regulation of 
FBW7 expression or mutations impairing the function have been found in a variety of human 
cancers leading to the assumption of FBW7 as a tumor suppressor 
89
. 
16 
It has been shown that FBW7 recognizes c-MYC and is responsible for its ubiquitinylation and 
degradation. It has been reported that during the cell cycle FBW7 is regulating c-MYC stability 
in G1 phase. Recently it has been found that another ubiquitin ligase β-TrCP attaches 
polyubiquitin chains on c-MYC thereby antagonizing FBW7 induced c-MYC degradation 
87, 89, 
111
. 
 
1.3.2.3.1.5. S-phase kinase associated protein 2 (SKP2) 
SKP2 is another F-box protein, which is regarded as an oncogenic protein since it degrades 
tumor suppressors and is involved in cell cycle progression. After gradually increased SKP2 
expression throughout the cell cycle, the highest levels of expression can be found in S-phase. 
In resting cells SKP2 expression is low. It is known to degrade the CDK inhibitors p21 and p27 
leading to a progressing cell cycle. Other SKP2 substrates are e.g. p57, BRCA2, RAG2, E2F1 
and MYC. In several types of tumors deregulation of SKP2 has been correlated to poor 
prognosis. Interestingly, besides leading to the ubiquitinylation of c-MYC and its degradation, 
SKP2 has also been reported to promote transactivation as well as MYC mediated 
transformation. Interaction between SKP2 and c-MYC seems to involve MB II as well as the 
bHLHZip domain 
91, 112, 113
. 
 
1.3.2.3.2. Binding partners to the C-terminal domain of MYC 
1.3.2.3.2.1. MYC interacting factor X (MAX) 
The helix-loop-helix leucine zipper protein MAX plays a central role in cellular processes and 
the transcriptional control of the MYC family. While MYC-MAX heterodimers positively 
regulate transcription, MAX homodimers or heterodimers of MAX with one of the MXD 
family members, MNT or MGA negatively regulate transcription of MYC target genes 
114, 115
 
MAX is a very stable protein however the MAX-MAX homodimer is not very stable. Two 
major isoforms,p21 and p22, of MAX have been identified 
116, 117
. The larger protein binds to 
DNA with higher affinity than the smaller protein. All proteins of the MYC-MAX-MXD 
network contain a bHLHZip domain that allows heterodimerization between MAX and one of 
the network members allowing binding to CACGTG-E-box sequences. The structure of the 
MAX homodimer bound to DNA has been determined by X-ray crystallization. It revealed an 
N-terminal α-helix, followed by two α-helices that are connected by a loop in the HLH domain 
and another α-helical coiled coil in the Zip domain 118. NMR studies of MAX without DNA 
showed an unfolded basic region that is stabilized and folded upon binding to DNA. Also the 
Zip is partly unfolded if MAX is not bound to DNA and the rest of the C-terminal half as well 
as both protein ends are unstructured. While MAX is needed for most of MYC’s functions 
recent reports have suggested that MYC is also able to perform some of its functions without 
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interaction with MAX 
119-122
. For example, a version of MYC, called MYC-Nick, has been 
shown to stimulate proliferation in rat fibroblasts, probably through translational mechanisms 
123, 124
. 
 
1.3.2.3.2.2. MYC-Interacting Zinc finger protein 1 (Miz-1) 
MIZ-1 is a zinc finger protein containing a Pox virus and Zing finger (POZ) domain. Depending 
on its interaction partners the MIZ-1 transcription factor is working as a transcriptional 
repressor or activator. It is involved in growth arrest and can normally be found in the cytosol. 
Furthermore it binds to initiator elements and activates the promoter of cyclin D1 and the 
adenovirus major late promoters 
125
. An amphipathic helix in MIZ-1 is interacting with the HLH 
domain of c-MYC thereby inhibiting transcription of MIZ-1. Association with MYC leads to its 
translocation into the nucleus. Furthermore MIZ-1 has been implicated in stabilizing MYC 
against degradation through ubiquitinylation 
126-131
. Recently it has been shown that gene 
repression by MYC together with MIZ-1 is dependent on the ratio between these two proteins  
132
. 
 
1.4. CELLULAR FUNCTIONS OF MYC  
MYC is involved in a number of cellular processes such as apoptosis, proliferation, cell growth, 
inhibition of differentiation, metabolism, telomerase activity, cell adhesion and motility as well 
as angiogenesis (Figure 5). Deregulation of MYC can lead to uncontrolled cell proliferation, 
immortalization, independence of growth factors, escape from immune surveillance and 
genomic instability 
14, 57
. Both normal functions as well as results of deregulated MYC will be 
described below. 
 
1.4.1. MYC in apoptosis 
In order to survive a cell needs pro-survival factors (cytokines), which are bound by cell surface 
cytokine receptors. These receptors signal through e.g. the AKT/ protein kinase B (PKB) and 
protein kinase A (PKA) families of serine/threonine kinases leading to the survival of the cell. 
Apoptosis is a function that leads to controlled cell death, which is very important for e.g. the 
development of organs and tissue or after e.g. DNA damage. There are two pathways for 
induction of apoptosis namely the mitochondrial and the receptor pathway 
133
. Several stress 
stimuli can lead to induction of apoptosis such as UV-light, radiation, chemotherapeutic drugs 
or cytokine deprivation. After activation of BAX or BAK, BCL-2 is bound by one of the 
proteins, diminishing the pro-survival function of BCL-2 leading to cytochrome c release as 
well as additional pro-apoptotic factors from the mitochondria 
16, 17, 134
. This in turn leads to the 
18 
activation of caspases and to cell death . Another way to activate cell death receptor FAS is 
through the FAS ligand (FASL) leading to the formation of a tetramer of the FAS receptor. The 
FAS-Associated protein with Death Domain (FADD) and the FAS receptor itself contain a 
death domain DD, which is necessary for their interaction. This in turn results in the recruitment 
of pro-caspases, which after cleavage will initiate the caspase cascade leading to apoptosis 
17, 135, 
136
.  
 
 
Figure 5. Functions of MYC. The transcription factor MYC is involved in the regulation of 
cellular processes such as cell cycle progression, cell growth, differentiation, metabolism, cell 
adhesion and motility, angiogenesis, apoptosis and telomerase activity. 
 
High expression of MYC in normal cells as well as in some cancer cells sensitizes them to pro-
apoptotic stimuli. Several MYC targets have been identified to play an important role in 
apoptosis. The death receptor pathways can be influenced by MYC on several levels. First of all 
MYC is able to activate the expression of FASL. This either leads to the direct suicide of the 
cell or in regard to MYC’s function in escaping immune surveillance it can also lead to the 
death of cancer cell targeting immune cells expressing FAS 
73, 137
.  
The serine/threonine kinase receptor interacting protein (RIP) is also activated by MYC in order 
to sensitize cells to tumor necrosis factor alpha (TNF-α) mediated apoptosis. In addition, an 
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indirect target of MYC is NF-κB and down-regulation of its activity leads also to inactivation of 
downstream pro-survival factors like BCL-2 
138, 139
. 
Two proteins of the BCL-2 (BCL-2 and BCL-XL) family are also regulated by MYC. The 
proteins of the BCL-2 family have either anti-apoptotic or pro-apoptotic properties. On the one 
hand MYC can induce association of BID with the mitochondria probably leading to the 
disruption of the functions of anti-apoptotic proteins such as BCL-2 or BCL-XL. On the other 
hand MYC can also indirectly inhibit the induction of the bcl-X and bcl-2 genes and their 
respective proteins. These proteins can in turn inhibit BAX, which is needed for the progression 
of apoptosis 
73, 137
. 
After the activation of MYC protein levels of ARF are increased. ARF then binds directly to 
Mdm2, thereby blocking its E3 ligase activity that normally leads to the inhibition of its activity 
as ubiquitin ligase for p53 and the sequestering of MDM2 in the nucleolus is initiated 
140
. The 
activation of p53 in turn leads to activation of proteins like PUMA, NOXA and BAX involved 
in apoptosis induction as well as the cell-cycle inhibitor p21. BAX is involved in the control of 
cytochrome c release, which then enables the apoptosome to form as well as the activation of 
caspases, inducing the final step of apoptosis 
141
. 
 
1.4.2. MYC in the cell cycle, cell growth and differentiation 
During development as well as wound healing cell mass is accumulated in order to grow and to 
develop organs and tissue or to close the wound. Cells will normally not grow without getting 
mitogenic growth signals from the surrounding environment. The process is called cell cycle 
and is highly regulated. The cell cycle is divided in different phases including G1-, S-, G2-phase 
and mitosis (also M-phase), which is further divided in prophase, metaphase, anaphase and 
telophase. After a division a cell will either remain proliferating or become a resting non-
proliferative cell in G0-phase.This decision will be made until the restriction point (R-point) in 
late G1-phase. From the beginning of G1 until the R-point, the cell is able to respond to 
mitogenic growth factors. If the cell continues to proliferate progression to each phase will be 
monitored by checkpoints in order to avoid DNA damage 
24, 142, 143
.  
Cyclin-dependent kinases (CDKs) together with cyclins are necessary for cell cycle progression 
at each checkpoint. While CDKs are stably expressed during the cell cycle, cyclins are 
synthesized and degraded when they are needed. In the beginning of the G1- phase the presence 
of mitogenic signals are sensed by the cell and the expression of cyclins D1, D2 and D3 are 
upregulated, which are needed for the activity of CDK4 and CDK6. The RB protein is 
phosphorylated at some few residues 
143
. In late state G1-phase after activation of cyclin E 
expression, the cyclin E protein binds to CDK2 in order to activate it. RB is further 
phosphorylated after the R-point leading to the activation of E2F transcription factors 
144, 145
. In 
turn expression of cyclin A1 and A2 is initiated, which are needed for S- and G2-phase. CDK 1 
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together with B-cyclins is present throughout mitosis after their expression has been activated.In 
the end of the mitosis the hyperphosphorylated RB protein is dephosphorylated. This is 
essential especially for cells in G0-phase 
143
. 
In order to control the cell cycle, so called cyclin-dependent kinase inhibitors (CKI) can 
function as negative regulators. Four INK4 proteins, called p15
INK4B
, p16
INK4A
, p18
INK4C
 and 
p19
INK4D
 are able to inhibit CDK4 and CDK6. The other four CDKs can be inhibited by p57
Kip2
, 
p27
Kip1 
and p21
Cip1
. In this way the cell cycle can be inhibited at every step if e.g. DNA damage 
would occur during cell division 
143
.  
Upregulation of MYC in quiescent cells is enough to initiate cell cycle entry. During the cell 
cycle MYC is expressed in all phases and its targets are also cell cycle related genes like CDK4, 
cyclin D1, cyclin E1, E2F1 and CDC25A explaining its importance during proliferation 
146
. In 
addition MYC is also able to induce CDK activating kinases, which lead to activation of 
CDK’s. Furthermore MYC also represses the CDK kinase inhibitors p21 and p27. While p21 is 
suppressed by the MYC/Miz-1 complex, MYC represses p27 by e.g. induction of miR-221 and 
miR-222, which silence the p27 mRNA 
147
.  
One important aspect of cell division is cell growth. A freshly divided cell needs to accumulate 
biomass and grow. For this process MYC is involved in several processes ribosomal and 
mitochondrial biogenesis and the metabolism of the cell as well as nucleic acid and protein 
synthesis. These mechanisms are regulated by MYC through transcriptional activation of genes 
involved in these processes. In ribosomal biogenesis for example MYC regulates all three RNA 
polymerases by interacting with their different regulatory factors. MYC is also involved in the 
regulation of the Transcription Factor A Mitochondrial (TFAM) protein, which is needed for 
mitochondrial transcription and DNA replication 
148, 149
.  
Differentiation is a process during which cells acquire a more specialized phenotype that is 
more characteristic for the tissue or organ to which each cell belongs to. Down-regulation of 
genes involved in proliferation are necessary. Indeed it has been shown that the MYC gene is 
strongly down-regulated during differentiation. However, recently it has been demonstrated that 
MYC not only blocks but is also able to facilitate terminal differentiation. This has been shown 
in several precursor cells including neuronal cells, pre-B-cells and skin stem cells 
123, 150-152
. Eμ-
myc transgenic mice have an impaired development of their B-lymphocytes 
153
. Neuronal 
progenitor cells could not differentiate when MYCN was expressed and a deletion of MYCN in 
mice induced premature differentiation of neuronal progenitor cells 
154
. Additionally, the 
cleavage product of MYC by calpain, so called MYC-Nick, has been reported to be increased in 
the cytoplasm of differentiating muscle cells 
123
. Calpains are activated by increased levels of 
calcium. In hematopoietic stem cells the overexpression of MYC leads to differentiation while 
MYC knockout reduces differentiation 
123
.  
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In murine embryonic stem cells c-MYC induces miRNAs that silence expression of genes 
involved in differentiation and modulating in this way the differentiation of these cells. Another 
way MYC is hindering differentiation is through repression of transcription factors including c-
JUN and GATA-1 
155
. 
Reprogramming of already differentiated cells like fibroblasts into induced pluripotent stem 
(iPS) cells has been shown to be possible with the expression of only four transcription factors, 
Oct-4, Sox-2, Klf-4 and c-MYC. Results from 3T3-L1 cells and mice suggested that MYC 
functions for inhibiting differentiation are necessary for MYC’s transforming activity 156-158. 
 
1.4.3. MYC in metabolism 
The metabolism of proliferating cells consists of several different processes including glycolysis 
resulting in ATP production, lactate production, intermediates of the TCA cycle as precursors 
for lipids, proteins and nucleic acids 
159-161
. Otto Warburg showed already in 1931 that the 
metabolism of normal non-proliferating cells differs from tumor cells. In order to produce 
energy normal cells use mitochondrial oxidative phosphorylation
162, 163
. In contrast, cancer cells 
have an increased glucose uptake and an enhanced glycolysis. In the recent years it has become 
evident that reprogramming of cancer metabolism is more complex than believed and the so-
called Warburg effect has been challenged. Importantly, altered metabolism in cancer cells may 
not be a consequence but play a more active part in tumorigenesis 
164
. 
MYC has also been reported to have major effects on metabolism by indirectly or directly 
targeting many genes involved in metabolism such as lactate dehydrogenase A (LDHA) and 
ornithine decarboxylase (ODC) 
148, 160, 165
. It has been shown to directly or indirectly regulate 
genes involved in aerobic glycolysis such as glucose transporters. 
148, 152
. Under non-hypoxic 
conditions MYC regulates glycolysis without HIF-1α, while it does co-regulate glycolysis with 
HIF-1 under hypoxic conditions 
166
. Furthermore MYC overexpression has been reported to 
increase glutamine uptake by an enhanced number of glutamine transporters 
149
. It has been 
demonstrated for tumors cells as well as for MYC overexpressing cells that these are dependent 
on glutamine in order to maintain the processes within the mitochondria 
167, 168
. MYC has also 
been shown to positively regulate mitochondrial biogenesis 
169-171
. Deletion of MYC leads to 
reduced oxidative phosphorylation, probably due to the reduced size and number of 
mitochondria. A link between MYC induced proliferation and increased mitochondrial function 
has been shown 
172
. In addition, MYC has been reported to be involved in lipid metabolism. Our 
group has demonstrated in neuroblastoma cells accumulation of lipid droplets after the 
inhibition of MYCN or with inhibitors against component of the fatty acid oxidation 
173
. 
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1.5. DEREGULATION OF MYC AND ITS INVOLVEMENT IN 
TUMORIGENESIS  
The MYC oncogene has been found to be deregulated in a large number of human cancers 
(Figure 6). Different mechanisms for deregulation of the MYC gene have been identified 
14, 58, 77, 
174
. MYC, which is located on chromosome 8, was found to be translocated to one of the 
Immunoglobuline (Ig) loci on chromosomes 14, 2 or 22 in BL. Mutations in the TAD of MYC 
especially in residues T58 and S 62 can only be found in BL 
77
. Additionally, translocations of 
MYC have been reported for several forms of leukemia. Mutations in MYC are rare compared to 
other oncogenes such as HRAS. However, insertional mutagenesis has been reported for MYC 
and seems to be more abundant. If during the process of insertional mutagenesis, retroviral 
promoters or enhancers are inserted into the genome close to an oncogene this will lead to the 
overexpression of the oncogene 
175
. The third possibility is amplification of one of the MYC 
genes, which can be found in cervical, colon cancer or osteosarcoma for c-MYC and in 
neuroblastoma and medulloblastoma for MYCN 
175
. 
 
Figure 6. Outcome of MYC deregulation. Aberrant MYC expression leads to uncontrolled proliferation, 
immortalization, escape from immune surveillance, independence from growth factors, genomic 
instability but can also result in apoptosis. 
The involvement of MYC in several cellular processes including apoptosis, cell cycle 
progression can explain the impact of its deregulated expression leading to e.g. a transformed 
cell with uncontrolled proliferation. In order for MYC to be successful in transforming cells, its 
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apoptotic function must be suppressed. This can either be achieved by keeping up the pro-
survival and growth factor signaling or by inhibiting pro-apoptotic signals 
24, 73, 125
. 
It has been shown that transformation of hematopoietic progenitor cells, breast epithelial cells 
and pancreatic β-cells can be induced by co-expression of BCL-2 and c-MYC resulting in the 
suppression of apoptosis 
73, 176
. Another mechanism to inhibit MYC-induced apoptosis by 
increasing MYC protein stability and its degradation 
152
. RAS activates RAF/MEK/ERK 
pathway and by phosphorylation of S62 stabilizes MYC. Furthermore the PI3K/AKT pathways 
is activated by RAS leading to the negative regulation of GSK-3β, which would phosphorylate 
T58 resulting in MYC ubiquitination and degradation 
73
. Both, RAS and MYC are able to 
transform rat embryo fibroblasts. Furthermore they have been found to be altered in BL as well 
as promyelocytic leukemia. In several tumors, apoptosis induced by MYC overexpression can 
be suppressed by mutation of the p53 gene leading to the interruption of apoptotic signaling 
152, 
177
. 
In order to study deregulated MYC in mice several transgenic mice models have been 
established. Since MYC overexpression leads to the death of the embryo, regulation of the MYC 
gene through insertion of an inducible or a repressible system can be achieved. Furthermore the 
results of MYC overexpression can be investigated in different type of tissues
178, 179
. Inactivation 
of MYC in the developed tumor first leads to tumor regression in all tumors. However the 
regression is dependent on the cell type and the genetic context. While in T-cell lymphoma the 
regression is due to cell cycle arrest, apoptosis and differentiation, the cells undergo 
differentiation in osteosarcoma 
180
. Also the duration of MYC inactivation is dependent on the 
tumor type. Lymphoma cells first differentiate and then senesce after inactivation of MYC and 
finally undergo apoptosis 
180-182
. In osteosarcoma the cells also first senesce or differentiate into 
bone cells and after reactivation of MYC apoptosis is induced in these cells 
181
. Hepatocellular 
carcinoma cells undergo senescence, differentiation and apoptosis upon MYC deactivation 
180
. 
However, its reactivation can lead to reappearance of the tumor 
181
. Inactivation of MYC was 
also achieved by expressing a dominant negative mutant called OmoMyc, encoding for the 
bHLHZip domain of c-MYC. The OmoMyc protein dimerizes with the bHLHZip domain of 
wild-type c-MYC thereby inhibiting heterodimerization with MAX  
183-185
. In K-RAS driven 
lung cancer this inactivation resulted in tumor regression with mild effects on normal 
proliferative tissue such as colon and intestine. These were encouraging results for MYC as a 
therapeutic target in cancer 
183-185
. 
 
1.6. BURKITT’S LYMPHOMA  
The first report describing Burkitt’s lymphoma (BL) as a lymphosarcoma of young children in 
tropical Africa is from the year 1958 by Dennis Burkitt. Shortly it has been discovered to be a 
highly aggressive non-Hodgkin’s Lymphoma. Three different subtypes of BL have been 
24 
described including the endemic, sporadic and immunodeficiency-associated variant 
186, 187
. All 
three subtypes have the chromosomal rearrangement of the c-MYC gene to one of the 
immuneglobuline (Ig) loci in common leading to the overexpression of c-MYC. However, there 
are clear differences between these three variants 
188
.  
Endemic BL occurs in children in the holoendemic malaria areas of Africa and the mean age of 
eBL peaks between 6-8 year old children. Tumors in children occur in the jaw, the eye and the 
abdomen 
187, 189, 190
. The co-factors in endemic BL (eBL) are malaria and Epstein-Barr virus 
(EBV) infection. Malaria antigens are thought to protect B cells carrying translocations from 
apoptosis and/or to increase infection of those B cells with EBV 
191, 192
. In the holoendemic 
malaria areas all children are repeatedly infected with malaria parasites and they also carry 
EBV. But it is still unclear why some children develop eBL, while the majority of children do 
not develop eBL 
191, 192
.  
While the co-factor for the immunodeficiency-associated BL is the human immunodeficiency 
virus (HIV), no co-factors are known for the sporadic BL (sBL). Both sporadic and HIV-
associated BL are occur worldwide and are not dependent on the age of the patient. In both 
forms less than 40% of the tumors contain EBV leading to the assumption that other co-factors 
are involved in the development of the disease. In sBL and HIV-associated BL tumors are 
mostly detected in the abdomen 
186, 193
.  
Treatment of BL is normally short-duration combination chemotherapy together with 
aggressive central nervous system (CNS) prophylaxis. Previously it has been thought that 
children with BL had a better survival rate than adults. However it has been shown that 
chemotherapy together with CNS prophylaxis is as curative for adults than for children. 
However, the outcome of the treatment very much relies upon the stage of the disease 
186, 193
.  
 
1.7. NEUROBLASTOMA 
1.7.1. Clinical representation 
Neuroblastoma (NB) is a rare cancer, but it is the most common extra cranial solid tumor in 
children. In the US it accounts for about 7-10% of all cancers in children and it is responsible 
for about 15% of pediatric oncology deaths 
194, 195
. While there are around 700 new children 
estimated in the US to develop NB, 15-20 new cases are reported in Sweden per year 
196, 197
. 
The diagnosis for most NB is made before the age of 5 years with a median occurrence of 22 
months 
198, 199
. The tumors arise from the developing neural crest and are most commonly found 
in the abdomen. The neural crest gives rise to peripheral neurons, enteric neurons, glia, 
melanocytes, Schwann cells and adrenal medulla (Figure 7). The tumors are associated with the 
adrenal gland or the sympathetic ganglia 
200, 201
. NB is a very heterogeneous disease that can be 
divided in different groups including spontaneous regressing tumors, treatable differentiated 
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tumors but also rapidly growing, metastatic tumors. The last group is mostly resistant to 
treatment and associated with poor survival 
200, 202
. Children that are diagnosed with tumors 
under the year of one and/or with localized tumors are normally curable with surgery and/or 
chemotherapy. In contrast, in children above one year, treatment of NB has proven to be more 
difficult. These children often have metastasis and outcome is mostly poor 
203
. Some cases of 
familial neuroblastoma have been identified 
204
. The anaplastic lymphoma receptor tyrosine 
kinase (ALK) has been found mutated in all cases of familial NB leading to its activation 
205
. Alk 
is normally expressed during the development in a specific area of the brain in mice, while it 
can hardly be detected in the adult mice 
206, 207
. While MYCN amplification (MNA) as well as 
loss of 1p or 11q are markers for poor prognosis, low MYCN together with high TrkA 
expression has been seen for tumors with favorable outcome 
202, 208
. 
 
 
Figure 7. Development of cells derived from the neural crest. The neural crest consists of 
multipotent stem cells, which undergo epithelial-mesenchymal transition (EMT) while they are 
migrating to the periphery of the embryo. During migration these cells are exposed to different 
signals resulting in a more differentiated cell. Neural crest cells can give rise to different kind of 
cells including swann cells, neurons and adrenal chromaffin cells. NB is believed to be derived 
from the sympatoadrenal lineage of neural crest cells. 
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1.7.2. Genetic changes 
In NB several genetic changes have been found including gene amplification, loss or gain of 
chromosomal loci or some few mutations. MYCN is amplified in about 25% of all primary NB’s 
70, 209
. Amplification of MYCN is a reliable marker for advanced stage, poor outcome and rapid 
tumor progression, whereas in non-MYCN amplified high MYC signaling could be correlated 
with high risk NB (132,136). It also has been found in combination with other alterations found 
in tumors with poor prognosis such as chromosome 1p deletion or gain of 17q as well as 
increased expression of multidrug resistance protein (MRP) 
210-212
. Deletion of the 1p36 region 
was found in over 70% of all NBs, while the loss of 11q and 14q also occur frequently. The 
gain of 17q has also been detected in NB 
200, 201
. The gain of whole chromosomes in NB is 
normally associated with a favorable outcome 
194
.  Gene amplification and somatic activating 
mutations of ALK have also been found in about 8% of NB, which in combination with MYCN 
amplification have been associated with adverse outcome 
195, 213
. Elevated expression levels of 
survivin, repp86 or PRAME have been correlated with poor outcome, while expression of the 
neutrophin receptor TrkA, CD44 or CAMTA1 has been reported for patients with a favorable 
diagnosis 
214
. 
The prognosis in NB patients with young age (< 18 months) as well as a differentiated histology 
has been reported advantageous 
215
. NB is normally treated in a combination of surgery, 
chemotherapy, radiotherapy and bone marrow transplantation depending on the risk group 
216
. 
Also treatment with13-cis-retinoic acid is used in the clinic in order to induce differentiation. 
Here, down-regulation of MYCN could be observed prior to differentiation 
70
. Despite recent 
progress in treatment the efficiency in treatment for high risk NB has improved little, resulting 
in a survival rate of approximately 15-30% 
194, 215. Even though NB’s are initially responding to 
chemotherapy, drug resistance is frequently developed in high-risk patients 
195, 203, 217, 218
. 
Therefore more tumor specific treatments and new strategies are needed in order to improve the 
survival and to decrease the side effects for the patients. Besides new compounds for e.g. down-
regulation of MYCN or ALK, other targets such as miRNAs could be developed in order to 
treat NB. Two different approaches have been described in paper I and paper III 
219, 220
. 
 
1.8. Targeting MYC in cancer 
Targeting MYC has long been thought to be not possible due to its important roles in many 
different cellular processes necessary for normal cellular functions. Furthermore, no defined 
binding cleft can be found in the MYC protein, since it is intrinsically disordered. Successes in 
the development of molecules targeting protein-protein interactions (PPI) or enzymes have in 
most cases been due to a structured protein and probably also an available tertiary structure for 
compound modeling (106,107). However, recent results have supported the view that MYC can 
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be targeted in tumors without damaging normal cells and tissue irreversibly 
183
. Since MYC-
driven tumors are often associated with fast progression and poor outcome like in NB. 
Different strategies to target MYC directly or indirectly have been developed 
221, 222
.The 
expression of MYC can be altered on both DNA and mRNA level by interfering with the MYC 
promoter or the transcription using e.g. siRNA or antisense nucleotides 
14
. Another possibility is 
targeting of the MYC protein itself and/or its interaction partners with small molecules. By 
inhibition of the heterodimerization of MYC and MAX or binding of one of the binding 
partners to MYC, it will not be able to exert its functions properly 
14, 221, 222
. A set of small 
molecules has been identified that interfere with the MYC/MAX interaction. These molecules 
bind to the bHLHZip domain thereby preventing MAX binding to MYC. Binding of the 
MYC/MAX complex to DNA could also be interfered with. Furthermore degradation of MYC 
protein could be increased. MYC target genes could also be inhibited either by modulating their 
expression or by inhibiting their protein products using siRNA or small molecules respectively 
59, 223
. 
 One example for an indirect way of targeting MYC is inhibition of BET bromodomain 
proteins, which are binding to acetylated histones in chromatin and increasing the number of 
transcription activators leading to transcriptional activation. Targeting this protein family by 
JQ1, a bromodomain inhibitor, has been reported to down-regulate MYC transcription and as a 
result also MYC target genes 
224, 225
.  
A number of MYC regulated miRNAs have been identified during the last years. One miRNA 
induced by both c-MYC and MYCN is miR-9, which has been shown to play a role in 
metastasis and invasiveness of tumors 
33
. Furthermore members of the miRNA cluster 17-92 
have been reported to be involved in supporting induction of lymphoma in Eµ-myc mice by c-
MYC. Additionally, we could show that MYCN induced the same cluster in neuroblastoma cell 
lines miR-18a and miR-19a suppressed estrogen receptor alpha (ESR-1) inhibiting 
differentiation of these cells (paper III) 
33, 220, 226-228
. The delivery of RNA based miR inhibitors 
has been difficult. However, cholesterol linked 2’ OMe oligonucleotides called antagomirs have 
been developed. Treatment with an antagomir for miR-10b could reduce the formation of 
metastasis in a breast cancer mouse model. Another method is to use locked nucleic acid-
modified oligonucleotides so called LNA-anti-miRs and they have been reported to down-
regulate their respective miR target in mice 
30, 229
. 
Despite the difficulties of targeting IDPs, several small molecules interfering with the c-
MYC/MAX interaction have been identified 
221, 230
. Most of these compounds have been found 
in a two-hybrid yeast screening by Edward Prochowniks’ group. Treatment of c-MYC 
overexpressing cells with a selection of these compounds resulted in cell cycle arrest, inhibition 
of cell growth and promoting apoptosis 
231, 232
. Binding to the bHLHZip of c-MYC has been 
confirmed using a number of biophysical experiments 
233-235
. However, there have also been 
some issues including solubility and fast turnover and probably also as a result these 
28 
compounds were found to not be effective in xenograft model for prostate cancer 
236, 237
. 
Interestingly, our group demonstrated in vivo effects of the most investigated compound 10058-
F4 in a MYCN transgenic tumor model of neuroblastoma 
173
. We could further show that 
inhibition of MYCN resulted in lipid droplet accumulation in NB cells. Our group was 
confirmed the binding of all small molecules previously shown to bind to c-MYC to MYCN, 
probably interfering with the MYCN/MAX heterodimerization leading to lipid accumulation, 
differentiation and inhibition of cell growth 
173, 219
. 
An indirect way of targeting MYC can be achieved by inhibition of mitotic processes like 
Aurora kinase inhibitors, which has been shown to induce lethal therapeutic responses in mice. 
The most promising molecule so far is JQ1, an inhibitor of Bromodomain containing 4 (BRD4) 
proteins, which have been shown to be involved in MYC induced transcription. JQ1 has been 
shown to prolong survival in several NB mice models 
238
. 
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2. MAIN EXPERIMENTAL BIOPHYSICAL METHODS 
2.1 Circular Dichroism (CD) 
Using the spectroscopic technique called Circular dichroism (CD) differences in the absorption 
of left and right circularly polarized light through chiral compounds are measured. The 
proportion of polarized light is never the same. CD is normally used to determine secondary 
structure of proteins or peptides. It can also be used to determine secondary structure changes 
upon interaction of two binding partners. Secondary structure measurements are normally 
performed in the far UV range (240-180 nm) 
239
. In this UV range the peptide contribution to 
the CD spectra dominates. Different structural elements have a unique spectrum with minima or 
maxima at specific wavelength. The spectra of an antiparallel β-sheet has a minimum at 218 nm 
and a maximum at 195 whereas the spectra of a completely α-helical protein two minima at 222 
nm and 208 nm with one maximum at 193 nm. Disordered, extended proteins have little 
ellipticity above the wavelength of 210 nm. The CD spectra of proteins can be used to 
determine their secondary structure content as well as to examine their structural changes due to 
temperature changes, denaturating solutions or mutants. However, CD is not able to determine 
the exact residues for the secondary structure identified and is not a high resolution method such 
as NMR or X-ray crystallography 
239-241
. 
 
2.2 Surface Plasmon Resonance (SPR) 
Surface plasmon resonance (SPR) is a technique based on an optical method using the refractive 
index close to the sensor surface for the detection of binding between two molecules. The most 
known instruments are the BIAcore machines 
242
. The surface of a sensor chip in the machine 
will create small flow cells (Figure 8A). All sensor chips are coated with a very thin gold layer, 
where one of the binding partners the so called ligand is immobilized to. There are different 
chips for different methods to immobilize one of the ligand to the surface of the chip using 
amine-, thiol- or aldehyde coupling. There are even chip for capturing His-tagged proteins 
243
. 
During all steps a buffer is continuously flown over the surface with the same speed . In order to 
determine binding the analyte is injected in increasing concentrations leading to a concentration 
dependent increase in the refractive index when the analyte is binding to the ligand. The change 
in the refractive index can be monitored and is visualized by a sensorgram (Figure 8B). The 
sensorgrams can be fitted through mathematical formulas enabling the determination of the rate 
of association and dissociation as well as the affinity. The system allows the analysis of 
proteins, low molecular weight compounds, lipids, nucleic acids, carbohydrates as well as cells, 
viruses and bacteria 
242-244
. 
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Figure 8. Concept of Surface Plasmon Resonance. A) The ligand is immobilized on the surface of the 
sensor chip. The analyte is flown over the surface. A light beam is directed towards the chip, leading to a 
change in the refractive index after the analyte has bound to the ligand. This response is visualized in a 
sensorgram. B) The ligand (here an His-tagged protein) is immobilized on a NTA-chip. After non-bound 
ligand is washed and the signal is steady, the analyte is injected. Association and disassociation of the 
analyte to its ligand can be seen. 
 
2.3 Small angle X-ray scattering (SAXS) 
Small angle X-ray scattering is a low-resolution method for the structural characterization of 
materials such as detergents, synthetic- and bio-polymers, organic or inoraganic film and 
biological macromolecules in solution. A monochromatic and collimated X-ray beam is 
directed onto the sample solution (Figure 9). The scattering pattern is recorded by a X-ray 
detector.  
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Figure 9. Scheme of a small-angle X-ray scattering experiment. A monochromatic X-ray 
beam is directed to the protein in solution and scattered. The scattered beams are collected 
by a detector.  
 
The macromolecules investigated can be quite large up to some Giga Dalton. SAXS allows for 
a quantitative analysis of equilibrium mixtures. In addition, SAXS provides insights into the 
overall size of the protein or complex in solution, their shape, the structural arrangement of 
domains in a protein as well as an estimation of the flexibility of a protein and the different 
conformations, it can adopt 
245
. There are several advantages with using SAXS for gaining 
structural insights. Besides being able to gain information about size and shape of proteins in 
solution, structural information can also be used for intrinsically disordered proteins or the fold 
of denatured proteins. Furthermore intermediate structures of proteins could be determined. A 
disadvantage is the low resolution that does not provide as in-depth structural details as X-ray 
crystallization 
245, 246
.  
 
2.4 X-ray crystallization 
The determination of the protein structure down to its atoms can be investigated by X-ray 
crystallization. For this purpose high protein purity and high concentrations are needed. The 
conditions, under which the proteins crystallize cannot be predicted. The bottle-neck in X-ray 
structure determination is the crystallization of the protein. Several aspects of the buffer are 
important for proteins to crystallize including ionic strength, the type of the ion (anions, 
cations), the pH of the solution, polymers such as polyethylene glycol in solution, organic acids, 
additives and the concentration of both protein and the components of the buffer 
247
. In addition, 
the temperature is an important factor. For a protein to form a crystal, the right equilibrium 
between protein concentration and the concentration of the precipitant solution must be 
determined. Protein crystals grow by slow controlled precipitation of the protein in aqueous 
solution in conditions that do not denature the protein (Figure 10). While the crystal is formed, 
intramolecular hydrogen and ionic bonds form and water is released, since some hydrogen 
bonds are sacrificed. On the surface of the protein in solution hydrophobic patches are lacking 
favorable hydrogen bonds. However, they are surrounded by ordered unfavorable water 
32 
molecules.  Therefore, the hydrophobic patches are normally buried by intermolecular 
interactions such as dipole-dipole or Van-der-Waals forces 
248
.  
 
Figure 10. The process from crystal screen to a 3D-structure. The screening for crystallization 
conditions leading to the crystallization of the protein is followed by data collection. A 
monochromatic X-ray beam is diffracted by the crystal. These reflections (black circles), which 
can vary in their intensities are collected by a detector and visualized on a film. Not all 
reflections (white circles) can be detected due to the position of the detector. Therefore data will 
be collected at different angles. Afterwards the data obtained is processed using several 
programs for structural determination. 
 
The crystal is mounted between a X-ray source and a X-ray detector, on which the diffracted 
beams can be seen as pattern. The diffractions are the sums of the electrons from the atoms in a 
protein. The diffraction patterns of different angles of the crystal ranging from at least 30-180 
degrees will be obtained in order to be able to construct a 3D-structure. The symmetry of the 
crystals determines the amount of data that is required to solve a structure (Figure 10).  
The visualization of the structure of the protein the phase problem must be solved. This can be 
achieved using different methods such as Molecular Replacement, Multiple Isomorphous 
Replacement (MIR) or Multiwavelength Anomalous Dispersion (MAD). The results are 
electron density maps, which can be used for the building of the model. However, very flexible 
regions might not be visible. All the data is processed using different programs for visualization. 
The preliminary model will be refined against the data, which will lead to a better model. This 
step might be repeated several times until no further improvements can be seen and a model of 
the protein structure can be obtained 
249-251
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3. AIMS OF THE STUDY 
 
The aims of this thesis was to characterize the structure of the c-MYC transactivation domain 
(TAD) using biophysical and biochemical methods as well as to investigate several small 
molecules in order for direct targeting MYCN in human cancer cells.  
The thesis is based on four different papers. In paper I several small molecules known to target 
c-MYC were characterized for their binding ability to MYCN as well as their effects on 
apoptosis, differentiation and lipid accumulation in MYCN-amplified neuroblastoma (MNA-
NB) cells. Furthermore, screening, identification and characterization of a set of several small 
molecules directly or indirectly targeting c-MYC and/or MYCN was performed in paper II. 
These molecules were tested for their ability to interfere with MYC/MAX interaction. 
Furthermore, the effect of these compounds was analyzed for effects on proliferation, 
anchorage-independent growth and foci formation. The aim of paper III was to identify and 
characterize MYCN regulated miRNAs in neuroblastoma and to analyze the functional outcome 
of the interaction. Importantly, the focus of paper IV was to investigate the structure of the c-
MYC TAD using biophysical methods including Circular Dichroism, Small-angle light 
scattering and X-ray crystallography. 
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4. RESULTS AND DISCUSSION 
4.1. Paper I. Targeting of the MYCN protein with small molecule c-
MYC inhibitors 
Targeting protein-protein interactions has been a more challenging task than finding a suitable 
compound inhibiting enzymes. For all protein-protein interactions (PPI), several domains of the 
interaction partners can be involved in the binding, which can be difficult to target. Progress has 
been made, however the traditional approach for drug development targeting ordered proteins 
has been through their three-dimensional structure. This resulted in the assumption that IDP’s 
should be excluded as potential drugable proteins. However, recently it has been shown that the 
interaction between disordered and ordered (e.g. the p53/Mdm2interaction) or interactions that 
undergo a disorder-to-order transition (e.g. the c-MYC/MAX interaction) can indeed be 
targeted. The aim of this study was to investigate the ability of known c-MYC inhibitors for 
binding to MYCN using SPR. Furthermore, the impact on known MYC functions after 
treatment with small molecules on MNA-NB cells was investigated in order to estimate their 
potential in cancer therapy. 
Several small molecules targeting the c-MYC/MAX interaction have been described 
252, 253
. 
Especially, compounds discovered in Edward Prochownik’s group have been the basis for 
biophysical studies demonstrating direct binding to the bHLHZip domain of c-MYC 
233-235
. 
Among these 10058-F4 is the most studied molecule showing inhibition of c-MYC/MAX 
binding as well as the ability to cause cell cycle arrest, apoptosis and inhibition of cell growth in 
a c-MYC dependent manner in tumour cell lines 
231, 232
. However, 10058-F4 had not been able 
to inhibit tumor growth in a prostate xenograft model overexpressing c-MYC 
237
. In contrast our 
group demonstrated a significant anti-tumorigenic effect could be demonstrated in a xenograft 
model using MYCN-amplified (MNA) cells. Furthermore, treatment of MNA-amplified NB cell 
lines with 100058-F4 resulted in induction of apoptosis, neuronal differentiation and the 
accumulation of lipids 
173
. Impairment with the mitochondrial metabolism by targeting MYCN 
leading to lipid accumulation might be a new strategy for future treatment of high-risk NB. 
Encouraged by these previous findings for 10058-F4 in NB cells, we next wanted to analyze the 
direct binding of selected molecules to the bHLHZip domain of MYCN. To this end, we chose 
10058-F4, three of its analogs, the 10058-F4 metabolite C-m/z232 as well as the structural 
unrelated compound 10074-G5, which binds to a different site in the c-MYC bHLHZip domain 
than 10058-F4. These molecules were investigated for their affinity to MYCN using SPR and 
their ability to interfere with the MYCN/MAX heterodimer was investigated with a proximity 
ligation assay (PLA). Furthermore functional effects of treatment with these compounds on 
growth inhibition, apoptosis, neurite outgrowth and lipid accumulation was determined. 
The C-terminal bHLHZip domain of the MYC family proteins is disordered but folds upon 
binding to MAX. In addition, the molecules investigated have a low solubility and needed to be 
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dissolved in DMSO increasing the difficulty to find a method suitable to detect protein-
molecule binding, since DMSO interferes with some biophysical methods. Therefore SPR was 
chosen in order to analyse binding. Affinities to c-MYC as well as MYCN could be determined 
for all molecules, except for the analogs 10058-F4(7RH) and #764. While 10058-F4(7RH) was 
previously reported not to bind to c-MYC and therefore was used as a negative control, the 
affinity for #764 could not be determined. This might be due to the low solubility of the 
compound and the temperature settings of the assay at 25°C. However, a concentration 
dependent increase in the curves of the sensorgrams could be detected indicating binding of 
#764 to the bHLHZip of MYCN and of c-MYC, respectively. The affinities to MYCN were the 
highest for 10074-G5, followed by #474, 10058-F4 and C-m/z 232. The standard errors were 
quite large for the SPR assay, which may have several reasons. The evaporation of the samples 
during the preparation process and the solubility of the compounds as well as the possibility that 
they might be precipitating during the assay run could have an effect on the affinities of the 
molecules to MYC. Furthermore, the Biacore machine used for the assay is very sensitive to 
very small differences in the concentration of compounds within the buffer or the compound 
solution. Despite high standard error values, the affinities obtained by SPR were higher than 
those previously described in the literature 
233, 235, 254
. One possibility might be the different 
methods used to determine the affinities. However there have also been studies indicating that 
the affinities might be lower than those previously reported. Importantly, a correlation between 
the affinities of the small molecules to the IC50 values determined for inhibition of cell growth 
could be observed. This correlation indicates that the strength of the interaction between the 
molecules is important for the efficiency to inhibit cellular growth.  
To further evaluate the ability of the molecules to interfere with the MYCN/MAX heterodimer, 
a PLA assay was performed in MNA-NB cells after 6 hours of compound treatment. In this 
assay the proximity of two proteins is detected by the use of two specific antibodies directed 
against each of the proteins. Specially designed secondary antibodies with a short unique DNA 
strand attached are used for visualization of protein-protein interactions. When two proteins 
interact the DNA strands come into close proximity and form a circle, which is being amplified. 
A fluorescent detection probe is attached to the DNA and the signal is detected by a 
fluorescence microscope. The assay revealed that the compounds 10058-F4, 10074-G5, #474 
and #764 were able to decrease the interaction between MYCN and MAX. In contrast, C-m/z 
232 did not have any effect on the MYCN/MAX heterodimerization. This might be due to a low 
affinity in order to prevent binding of MAX to MYCN. Importantly, the non-binder 10058-
F4(7RH) did not show any effect on the heterodimerization of MYCN and MAX. The same 
molecules decreased the interactions of MYCN and MAX, were also the most potent in 
inducing apoptosis in a doxycycline regulated MYCN-expressing cell line Tet21N. After 
treatment with molecules increased apoptosis in MYCN-expressing cells compared to cells with 
low MYCN levels could be observed. Again the 10058-F4 metabolite was not able to induce 
apoptosis in MYCN-expressing or in non-expressing cells indicating that the compound 10058-
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F4 is responsible for the effects observed in vivo. Both analogs (#474 and #764) were the most 
effective in inducing cell death. 
In order to investigate the effects of the molecules on MYCN protein levels Western blot 
analysis was performed. Only 10058-F4 and 10074-G5 were found to reduce MYCN protein 
levels. The small molecules #474 and #764 were most effective compounds in inducing 
apoptosis, while treatment with 10058-F4 and 10074-G5 resulted in neurite outgrowth and lipid 
accumulation in MNA NB cells.  
The two molecules 10058-F4 and 10074-G5 were able to reduce MYCN/MAX interaction and 
to decrease MYCN protein levels. Furthermore, treatment with either of these two compounds 
lead to enhanced apoptosis in MYCN-expressing NB cells, neurite outgrowth and lipid 
accumulation. The two analogs #474 and #764 were able to interfere with MYCN/MAX 
binding. They were also very potent in inducing apoptosis at low doses however no effect on 
protein levels could be shown. After treatment with one of the analogs neither neurite outgrowth 
nor lipid accumulation could be observed in MNA NB cells. This might indicate that these 
processes occur as a result of MYCN down-regulation in MNA NB cells. The metabolite C-m/z 
232 showed the lowest affinity and was not able to interfere with the MYCN/MAX 
heterodimerization or to induce apoptosis. Compared to 10058-F4 and 10074-G5 the effect on 
neurite outgrowth was less pronounced after treatment with high concentrations. However the 
metabolite was able to induce some lipid accumulation but only after treatment with higher 
concentrations indicating that this might not be due to a specific response to MYCN inhibition 
but rather due to stress induced by the high concentrations of compound present in the cell.  
In summary, we showed that the small molecules previously shown to bind to c-MYC also 
bound directly to MYCN. Interference with the MYCN/MAX heterodimerization was induced 
MYCN-dependent apoptosis in MNA NB cells. Furthermore, the decrease of MYCN/MAX 
interaction also leads to other MYCN-selective responses such as lipid accumulation and 
differentiation following the decrease in MYCN. MYC-driven tumors are often associated with 
poor prognosis and survival. In the latest years the possibility of targeting MYC directly in 
cancer has become evident
183
. Several groups are currently screening for small molecules that 
directly target MYC. Furthermore already existing compounds are being improved regarding 
their solubility, their cellular uptake and their affinity to MYC 
237, 254, 255
. Here we have shown 
as proof of principle that targeting MYCN in NB is possible and might be a new treatment 
strategy for high risk NB.  
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4.2. Paper II.Identification of low molecular weight compounds that 
target the MYC:MAX protein interaction and inhibit MYC-dependent 
tumour cell growth 
The compounds described in paper I have been so far the most promising small molecules 
targeting MYC. To date there are no drugs present targeting MYC in the clinic since the 
compounds available until now show low potency at high concentrations and/or off-target 
effects. Therefore more potent MYC targeting molecules with less off-target effects are needed. 
In this study a cell based screening assay was performed identifying several potential small 
molecules interfering with the MYC/MAX interaction
221
. 
First the cell-based Bimolecular Fluorescence Complementation assay (BiFC) was chosen as a 
method for an initial screening of a chemical library for interference with the MYC/MAX 
heterodimerization. For the screen the yellow fluorescent protein is fused into two halves. While 
one half is fused to c-MYC the other is attached to MAX. When these two proteins come into 
close proximity the YFP halves can fuse and start to fluoresce, which can be detected using a 
fluorescence microscope. After optimization, 2000 small molecules were screened and 15 
compounds were identified in the first round.  
These hits were then validated in a Gaussia luciferase protein fragment complementation assay 
in HEK293 cells using the same principle as in the BiFC assay. In this refined screen, the ability 
of the compounds to disrupt both c-MYC/MAX as well as MYCN/MAX heterodimerization 
was assessed. Out of 15 compounds six (#2, 6, 7, 9, 11 and 14) were found to decrease 
MYC/MAX and MYCN/MAX interaction.  
All six compounds were then tested for their ability to directly target the MYC/MAX and 
MYCN/MAX interactions by mixing the fusion proteins and measure the effect of the small 
molecules on heterodimerization. While compound #2 was very efficient in disrupting 
MYC/MAX and MYCN/MAX in vitro it was less effective in cells, probably due to poor 
uptake, degradation within the cell or an efficient efflux. In contrast, the small molecule #7 
showed little effects in this assay leading to the assumption that it might indirectly target the 
MYC/MAX interaction. Compounds #6, 9 and 11 were also able to inhibit MYC/MAX 
heterodimerization. Using Western blot analysis of treated cells the ability of the compounds to 
down-regulate protein levels was tested. Only compounds #7 and 14 could be shown to down-
regulate MYC protein levels. It was further demonstrated that the compounds #2, 6, 9, 11 and 
14 were not able to interfere with the interaction of neither FOS/JUN nor GCN4/GCN4 
suggesting specific targeting for MYC/MAX.  
All small molecules were shown to have inhibitory effects on cell growth in MNA NB cell lines 
using a WST-1 assay. Compounds #7 and 9 were more potent in growth inhibition than #2, 6, 
11 and 14. While compounds #6, 7 and 11 were found to be more effective in MNA cell lines 
compared to non-MYCN amplified cell lines, no such effect could be observed for compounds 
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#2, 9 and 14 indicating that these molecules could interfere with MYCN as a transcription 
factor. Indeed, a reduction of β-gal activity greater than 50% was obtained for all compounds 
except of #9.  
Growth inhibition could also be seen with compounds #2, 6, 7, 9, 11 and 14 in two BL cell 
lines. Two molecules, #6 and 7, were the most effective in both cell lines, while #2, 11 and 14 
inhibited growth to a lesser degree. Compound #9 was effective in one of the cell lines. 
Compound #2 was chosen for further optimization since it was shown to interfere directly with 
the MYC/MAX heterodimerization. This molecule was found to be less active in cells than in a 
direct protein-protein inhibition assay. Therefore analogs were selected from the NCI/NIH 
library and examined for their ability to interfere with the MYC/MAX and MYCN/MAX 
interaction in the GLuc assay. Inhibition was increased for analog #2:7 compared to its mother 
compound.  
The effect of the analog on MYCN/MAX heterodimerization was further demonstrated using an 
in situ Proximity Ligation Assay (isPLA) with antibodies against MYCN and MAX. Again a 
fluorescent signal will only be seen if MYCN and MAX are in close proximity. Two MNA cell 
lines and one non-MYCN amplified cell line were investigated for MYCN/MAX 
heterodimerization with and without #2:7 treatment. As expected, the interaction of MYCN and 
MAX could only be detected in MNA-cells and the signal was reduced after treatment with 
#2:7.  
Direct binding to the bHLHZip of both c-MYC and MYCN could also be shown for two 
analogs (#2:7 and 2:16) in an SPR assay, while #2 showed unspecific binding. In addition, 
treatment with compound #2:7 decreased transcription in a Luciferase assay using an E-box 
containing promoter and resulted in a reduction of proliferation. In addition, both foci formation 
and anchorage-independent growth were inhibited by #2:7. 
In summary, six compounds were identified due to their inhibition MYC-dependent cell growth 
out of the initial 2000 molecules screened. The analog (#2:7) of the #2 mother compound  was 
further characterized showing direct binding to the bHLHZip domain of both c-MYC and 
MYCN. In addition, this molecule was demonstrated to interfere with the MYCN/MAX 
interaction. Importantly treatment of NB cells resulted in a decrease in proliferation, foci 
formation and anchorage-independent growth. Here, a robust screening method has been used 
in order to identify new interesting molecules to target MYC directly or indirectly. The effect of 
these molecules could be further investigated in e.g. xenograft models in mice in order to 
investigate their efficiency in vivo. 
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4.3. Paper III. MYCN-regulated microRNAs repress estrogen 
receptor-α (ESR1) expression and neuronal differentiation in human 
neuroblastoma 
One of the markers for poor prognosis and fast progression of NB is MYCN-amplification
256, 257
. 
However, the mechanisms underlying tumor development in MYCN-overexpressing NB is not 
well understood. In the recent years it has become clear that deregulated expression of small 
non-coding RNA’s, called miRNAs is involved in tumorigenesis 32, 205. Therefore, we 
investigated regulation of miRNA by MYCN in NB cell lines.  
The Tet21N NB cell line with inducible MYCN-expression was used in a miRCURY Locked 
Nucleic Acid (LNA) array in order to identify MYCN-regulated miRNAs. Comparing MYCN-
expressing to non-expressing cell lines we identified several down-regulated miRNAs in cells 
expressing MYCN. Additionally we found several up-regulated miRNAs including the miR-
17~92 cluster (miR-17, miR-18a and miR-19a). These results were confirmed by Northern blots 
using RNA from Tet21N cells as well as quantitative polymerase chain reaction (qPCR) 
analysis of human NB tumor samples. Direct binding of MYCN/MAX to upstream E-box 
sequences of the miR-17~92 cluster was verified by chromatin immunoprecipitation (ChIP). In 
addition, increased acetylation of histone H4 could be shown for these regions indicating that 
they are actively transcribed. 
It had previously been shown that the miR-17~92 cluster contributed to NB tumorigenesis and 
the involvement of two of its miRNAs, miR-17 and miR-20a had been examined 
32
. However, 
the biological outcome of miR-18a and miR-19a overexpression had not been investigated. In 
order to test the impact of LNA knockdown of miR-18a and miR-19a in MYCN-amplified cells 
fluorescence activated cell sorting (FACS) analysis was performed. Knockdown of miR-18a 
lead to a robust decrease in cell cycle progression, while the effect was less pronounced after 
miR-19 knockdown. It has previously been shown that MYCN expression is down-regulated in 
differentiating neuronal cells and conversely that down-regulation of MYCN results in neuronal 
differentiation of NB in vitro 
70
. Importantly, long-term knockdown of miR-18a also resulted in 
differentiation of MNA-NB cells. Downstream target genes of miR-18a and miR-19a were 
predicted using TargetScanHuman and PicTar. Interestingly one of the genes that scored high 
was the estrogen receptor alpha (ESR1), encoding for the nuclear hormone receptor (ERα). The 
repression  of ESR1 expression by miR-18a and miR-19a was shown in a luciferase reporter 
assay in HEK293 cells which were transfected with ESR1 3´UTR sequence.  
Transfection of the breast carcinoma cell line MCF-7 expressing high levels of ESR1 with miR-
18a or miR-19a precursor molecules lead to down-regulation of ESR1 mRNA and estrogen 
receptor alpha (ERα) protein. In Tet21N cells ERα levels recovered after long-term repression 
of MYCN expression. Conversely, inhibition of MYCN protein levels was followed by 
reduction in miR-18a and miR-19a levels. The same effect could be demonstrated in MYCN3 
cells, containing a MYCN-inducible expression system. In order to investigate the role of ESR1 
in NB cell lines, SK-N-BE(2) cells were transduced with ESR1 cDNA resulting in growth arrest 
and neurite outgrowth. The expression of ERα in the sympathetic nervous system could be 
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demonstrated by immunohistochemistry staining suggesting a role during normal neuronal 
development. In addition we demonstrated a reverse relationship between expression of MYCN 
and ESR1. In patients, high expression of MYCN leading to low expression of ESR1 is coupled 
to poor prognosis while low MYCN and high ESR1 expression correlated with improved event-
free survival using bioinformatical analysis of microarray data of NB tumors.  
 
Figure 11. Proposed mechanism of MYCN-regulated miR-17~92 cluster (especially miR18a 
and miR-19a), which in turn repress ESR-1 expression and as a consequence block 
differentiation in NB cells. 
Taken together, we showed that MYCN expression in NB cells leads to induction of the miR17-
92 cluster and that miR-18a and miR-19a expression decrease of ESR1 on mRNA and protein 
levels thereby inhibiting NB differentiation (Figure 11). Hence, targeting MYC-regulated 
miRNAs could be a new strategy for cancer therapy In MYC-driven cancers. High-risk tumors 
are often poorly differentiated and down-regulation of miR-18a may induce differentiation in 
MYCN-amplified NB. However, a suitable delivery system for anti-miRs often has to be 
developed before being able to use it in therapy.  
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4.4. Paper IV. Structural analysis of the c-MYC transactivation 
domain reveals highly flexible regions in an extended rod like 
structure 
Intrinsically disordered proteins have been reported to be involved in human diseases due to 
protein misfolding resulting in loss of function, gain of a toxic function or protein aggregation. 
Targeting IDPs is challenging and little is known about their structures, since some only fold 
upon binding and others remain unstructured making structural determination difficult. 
Furthermore, IDPs are thought to be able to adapt different types of structures depending on 
their binding partners, leading to a variety of conformations that the protein might adapt. MYC 
is one of these proteins 
45, 47, 49
. The C-terminal part of MYC has been shown to fold upon 
binding to its interaction partner MAX and the crystal structure is solved in complex with DNA 
80
. In contrast, little is known about the structure of N-terminal domain, which has been reported 
to bind to a large number of binding partners 
75, 78
. Previous structural and biophysical studies 
have determined secondary structure for smaller domains within the c-MYC-TAD. The c-
MYC-TAD (residues 1-88) was reported to contain two short α-helical stretches as well as a 
short β-sheet stretch. 
 Here, we have used CD to estimate the secondary structure content of the c-MYC-TAD. 
Importantly, we investigated the structure of the c-MYC-TAD using SAXS and X-ray 
crystallization. The analysis of the c-MYC-TAD CD spectra obtained indicated 9 % α-helices, 
30 % β-sheets and 61% unstructured domains. This is in contrast to the predictions based on the 
amino acid content revealed a higher content in α-helical structure (18%), much less β-sheets 
(3%) and 79% unstructured domains. However, the differences could be due to the fact that 
structural predictions are based on previously determined structures with homology. Since 
IDP’s can take several different structures and might fold upon binding to their partners, it is 
difficult to estimate their secondary structure content in an unbound state. Therefore the 
prediction program might only predict one of many possible secondary structures. Furthermore 
in the unbound state the c-MYC-TAD might take several confirmations with varying secondary 
structure content due to the flexibility of the protein. 
In order to analyze the overall structure of the c-MYC-TAD SAXS was used. Forward 
scattering revealed the presence of a pentameric complex in solution. In support the size 
exclusion profile showed a complex of 3-4 times the monomeric weight, after comparison with 
a kit containing different globular proteins with known molecular weight (MW). The 
discrepancy in oligomer size might be due to the difference in the methods. However, the c-
MYC-TAD is a very flexible domain, which runs in a different manner through the same 
column compared to a more globular protein. The oligomeric state of the c-MYC-TAD might 
by itself lead to an increase in its structural content, which might account for the discrepancy 
between the predicted and obtained secondary structure. Importantly, we showed that the 
pentameric complex contained structured domains, which were connected by flexible linkers. 
The pair distribution constant revealed a single peak with a shoulder, indicating the presence of 
an extended and flexible protein. The overall shape fitted best to an elliptical cylinder.  
42 
In another approach we attempted co-crystallization experiments with a Fab-fragment, derived 
from the 6A10 monoclonal antibody in order to stabilize the c-MYC-TAD. First, binding after 
digestion of the antibody was determined using surface plasmon resonance (Biacore), revealing 
a high binding affinity in the low nM range. After microcrystals appeared in the fine screen, 
Western Blot analysis of one of the crystals indicated that both c-MYC-TAD and the Fab 
fragment might be present in the crystal. However, since the crystal dissolved immediately in 
solution, possible precipitations attached to the crystal could not be washed off, which may have 
lead to a false positive result. Two data sets from two different crystals were obtained, however 
after determination of the unit cell, the data could not be processed any further.  
The Fab fragment is not a natural binding partner but a solved crystal structure of the c-MYC-
Fab complex might still give insights on a possible confirmation as well as the possibility for 
the c-MYC-TAD of gaining secondary structure after binding to a stabilizing partner. 
Interactions between the c-MYC-TAD and its binding partners might be too weak for 
crystallization of larger regions. The possibility to determine a structure of such a complex 
might also depend on the secondary structure of the binding partner. However, methods such as 
SAXS paired with NMR and CD might also lead to more detailed structural information of the 
c-MYC-TAD alone as well as in complex.  
In summary, we determined that c-MYC-TAD forms a pentameric complex in solution. Our 
analyses revealed an extended, flexible protein with structured domains connected by flexible 
linkers leading to an elliptic overall structure. It has previously been shown that the bHLHZip of 
c-MYC produced in bacteria can form tetramers. Here, we have shown that the c-MYC-TAD 
forms a pentameric complex in solution. This might indicate that the MYC protein indeed is 
able to oligomerize. However, this would have to be shown for the full-length protein and might 
lead to further insights of MYC function. 
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5. CONCLUSIONS AND FUTURE PERSPECTIVES 
During the recent years overall survival has increased in NB patients. However, not much 
progress has been made regarding the treatment of high risk NB (including patients with 
MYCN-amplification or 11q-deletion) and the survival rate for these children is still under 50%. 
Furthermore NB is responsible for 12% of all cancer related deaths in children 
211
. Correlations 
between MYCN expression and the multidrug resistance-associated protein (MRP) have been 
described. Indications of activation of MRP by MYCN overexpression have been made, which 
could lead to acquired drug resistance and failed NB treatment 
202, 212
.  
Most traditional strategies for small molecule development have been to target structured 
proteins such as the active domain of enzymes. In contrast, targeting IDPs e.g. MYC has been a 
challenging task since the flexibility of these proteins and their low structural content has been 
regarded as undrugable. Furthermore, the existence of a three-dimensional structure has of great 
help in drug design in the past and will be an important advantage also in future
47, 49
. Inhibition 
of MYC function in vivo using the dominant negative protein Omomyc protein has shown anti-
tumorigenic effects in mice with reversible effects on normal, fast proliferating tissues. 
Therefore targeting MYC has become a desirable new approach for cancer therapy 
183
. 
However, to date no drugs directly targeting MYC/MAX or MYCN/MAX can be found in the 
clinic due to their low solubility and/or their poor effects in vivo of the compounds analyzed o 
date.  
In the recent years small molecules directly targeting the MYC/MAX interaction have been 
identified. In paper I, we have shown that directly targeting MYCN leads to apoptosis, 
differentiation and lipid accumulation 
173, 219, 221
.These findings emphasize the possibility of 
targeting MYC directly. Furthermore, we could see a correlation between decreased protein 
levels of MYCN in MNA NB cells and lipid accumulation. Our group has previously shown 
this metabolic reprogramming in response to 10058-F4 which we now extend also to other 
molecules. Improved MYC inhibitors could be used for cancer therapy in future. Two different 
approaches could lead to this goal either by improving existing small molecules or by new 
screening approaches (paper II) for improved compounds that might lead to more efficient and 
specific inhibitors for MYC/MAX interaction. In paper II a robust cell-based protein 
complementary assay was developed for this task showing the success of such an approach. In 
both paper I and paper II small molecules have been shown to be more potent in MNA NB 
cells than in non-amplified NB in inducing apoptosis and inhibition cell growth indicating their 
selectivity towards MYCN. Promising molecules could be further developed and tested in 
animal models for their efficiency. 
In paper III MYCN mediated inhibition of differentiation through up-regulation of miRNAs, 
miR-18a and miR-19a leading to repression of ESR1 has been demonstrated. The miR-17~92 
cluster has been described having oncogenic functions in cancers such as NB, B-cell lymphoma 
and anaplastic thyroid cancer. Binding of c-MYC and/or MYCN to the promoters followed by 
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activation has been reported for several other miRNAs including miR-9, miR-181a, miR-15b, 
miR-130a as well as miR-214 
258, 259
. These miRNAs might be targeted in two different ways. 
One possibility would be to target MYC/MYCN in order to inhibit downstream targets 
including miRNAs, which could also be specifically inhibited by so called anti-miRs 
205
.  
Another strategy is the possibility of targeting downstream targets of MYC or MYC regulated 
miRNAs. Our group has demonstrated that MYCN regulates several members of the respiratory 
chain. These members have previously been shown to contribute to metastasis and are 
correlated with poor survival 
165
. Metformin, used for treatment of diabetes, has been proposed 
to exert anti-tumorigenic activities through inhibition of complex I the respiratory chain 
260
. 
Furthermore it has been proposed to target miRNA-regulated processes such as 
dedifferentiation in cancer cells 
261
. Consequently, treatment with metformin of MYCN-
amplified and non-MYCN amplified NB would be an interesting new approach for future 
therapy. 
Previous effort has been focused on the C-terminal domain bHLHZip of c-MYC, which has 
been crystallized in a heterodimer with MAX bound to DNA. This domain is known to form 
two α-helices connected by a loop upon binding to MAX. In paper IV we have analyzed the c-
MYC-TAD using SAXS showing an overall extended, flexible structure. Some structure was 
also determined using CD and SAXS analysis indicated the presence of multiple structured 
domains connected by flexible linkers. SAXS has emerged as an interesting method for 
characterizing intrinsically disordered proteins.  
Importantly, the c-MYC-TAD has been shown to interact with a large amount of different 
proteins 
75, 78
. Molecular basis underlying these interactions are in most cases unclear since this 
domain is highly flexible an only displays very little secondary structural content. The c-MYC-
TAD is necessary for all of MYC’s function 58. Structural and biophysical characterization of 
the c-MYC-TAD alone as well as in complex with its binding partners will open new 
possibilities e.g. finding inhibitors for different protein-protein interactions. Specific inhibition 
of interactions between the c-MYC-TAD and its binding partners might also shed new light on 
the biological functions of these particular complexes are involved in. Furthermore, this might 
be an additional approach of targeting MYC in specific types of cancer. TRRAP binds to the c-
MYC-TAD and has been reported to inhibit the differentiation of brain tumor initiating cells in 
glioblastoma multiforme 
106
. Splicing forms of another interaction partner BIN-1, normally 
inhibiting MYC function have been suggested to play a role in tumorigenesis. This might be the 
result of loss of interaction between the c-MYC-TAD and BIN-1. To date little is known of the 
molecular basis underlying binding of the c-MYC-TAD and its binding partners. SAXS, NMR 
as well as SPR and CD could be used to study these interactions between both the wt and 
mutant forms of c-MYC-TAD and its interactors. Further insights might lead to new approaches 
for further analyzing MYC function as well as for treatment in certain types of human cancers.  
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In paper IV we have analyzed the c-MYC-TAD using SAXS showing an overall extended, 
flexible structure. Some structure was also determined using CD and SAXS analysis indicated 
the presence of multiple structured domains connected by flexible linkers. SAXS has emerged 
as an interesting method for characterizing intrinsically disordered proteins. In combination 
with NMR, the possibility arises for determination of structures for disordered and flexible 
proteins, which has not been possible before. These methods could be used to obtain overall 
structures of the c-MYC-TAD bound to binding partners and to further characterize these 
interactions. 
In addition, structural insights of the c-MYC-TAD might also be used for structural and 
functional comparison of different transactivation domains in general. This may lead to 
common or exclusive features for different transcription factors, which might result in new 
insights concerning their functions. SAXS has emerged as an interesting method for 
characterizing intrinsically disordered proteins. In combination with NMR, the possibility arises 
for determination of structures for disordered and flexible proteins, which has not been possible 
before. These methods could be used to obtain overall structures of the c-MYC-TAD bound to 
binding partners and to further characterize these interactions. 
In conclusion, different ways of targeting MYC/MYCN have been described in this thesis. This 
could either be achieved by targeting the interaction of MYC/MYCN with MAX using small 
molecules or by targeting MYCN-regulated miRNAs in NB. Furthermore, structural 
characterization of the c-MYC-TAD might lead to the possibility of targeting specific 
interactions between this domain and one of MYCs binding partners. All these possibilities can 
be considered as future strategies to target human cancers. 
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